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Endometrial cancer (EC) is one of the most common gynecological cancers with extensively rising 
incidence worldwide. Norway is among the countries with the highest rates of EC. Although, most 
of the established risk factors for EC are well described, there are few studies from Norway 
investigating them in a cohort design. Moreover, modern clinical medicine, especially oncology, is 
moving towards personalized and individualized diagnostics and treatment approaches, and 
therefore there is a great need for studies focusing on detecting of biomarkers and changes in gene 
expression profiles long before the diagnosis takes place. 
The main aim of this PhD project was to evaluate the risk factors that mostly contribute to the 
development of EC in Norwegian women, and to assess whether these risk factors have any 
influence on blood gene expression prior diagnosis.  
The Norwegian Women and Cancer Study (NOWAC) is a prospective cohort study with 
approximately 172 000 female participants recruited from the whole Norway since 1991. The 
participants answered questionnaires regarding lifestyle, diet and health. Further a subset of 
approximately 50 000 women from NOWAC cohort were randomly recruited to NOWAC 
Postgenome Cohort and provided blood samples.  For paper I, self-reported coffee consumption 
was evaluated in the light of possible protective effect against EC development in Norwegian 
population. In paper II, we studied the association between lifetime number of years of 
menstruation and EC. It was investigated whether this association is attenuated by other well-known 
modifiable lifestyle risk factors such as high BMI, diabetes, incomplete pregnancies and 
menopausal hormone therapy (MHT). In Paper III, using the systems epidemiology approach, we 
evaluated the impact of the major EC risk factors on prediagnostic blood gene expression signatures 
in a subcohort of 79 EC cases and 79 matching controls. 
In line with previous reports, we demonstrated inverse association between coffee consumption and 
EC, which was especially pronounced in obese women and current smokers. However, in contrast 
to other studies this was observed only in heavy coffee drinkers (in our study those who drank ≥8 
cups/day). In paper II we showed a statistically significant linear relationship between LNYM and 
EC risk, which remained significant after adjusting for BMI, diabetes, MHT and incomplete 
pregnancies. Paper III demonstrated that changes in parity status are associated with a number of 
alterations in immune gene sets in controls compared with EC cases, thus providing a novel view of 
pregnancy-associated EC protection. 
In conclusion, the main findings of this work demonstrate the complexity of endometrial 
carcinogenesis and emphasize necessity of further investigations on both reproductive and lifestyle 
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risk factors combined with translational research approaches. The results showing gene expression 
changes connected to long-term protective effect of parity might serve a solid foundation for further 
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1. INTRODUCTION   
 
1.1 Endometrial cancer 
The present PhD thesis and following articles focus on endometrial cancer (EC), malignancy that 
originates from the inner epithelial lining of the uterus (endometrium) and comprises ca. 90% of all 
cancer uteri tumors (1). 
 
1.1.1 Epidemiology  
EC is one of the most common gynecological malignancies worldwide with a strong geographical 
variation in cancer incidence rates (Figure 1) (2). It is the fourth frequent cancer type in women in 
developed countries after breast, colon and lung cancer (3). Among gynecological cancers, EC takes 
the first place in developed countries and the second place world-wide after cervical cancer. 
 
Figure 1. Age-standardised incidence rates of cancer of the uterine corpus per 100 000 person-years (all ages). 
Illustration used with permission, copyright 2005 by Elsevier Limited 
World age-standardised incidence rate (ASR) statistics shows that Northern America, 
Central/Eastern Europe, Northern Europe, Australia are among the countries with the highest 
incidence rates in 2012 (4). In contrast, the majority of African countries (except Southern Africa) 
and countries of South-Central Asia had the lowest incidence rates (Figure 2A). However, such 
contrast variation in incidence could be partly explained by varying data quality worldwide (5). 
Among the European countries, the highest world ASR for EC were in Macedonia and Luxembourg 
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(39.4 and 35.3 per 100 000 respectively) compared to the lowest in Greece and Hungary (10.5 and 






Figure 2. Age-standardised endometrial cancer incidence. (A) Age-standardised incidence per 100 000 population 
world-wide, 2012 estimates. (B) Age-standardised incidence per 100 000 population in Europe, 2012 estimates. 
Adapted with permission, copyright 2014 by John Wiley and Sons and 2013 by Elsevier Limited 
EC in Norway occupies one of the leading positions among European incidence rates (the 8th 
highest in Europe), with World ASR 24.0 per 100 000 in 2012 and Norwegian ASR 27.6 per 100 
000 estimated for 2012-2016. The incidence rates has grown dramatically over the last decades in 
Norway, given that the ASRs were 11.3 per 100 000 and 19.7 per 100 000 in the periods 1957-1961 
and 1982-1986 respectively (7). 
According to the last updates from Norwegian Cancer of Norway, there were 742 new cases 
registered in 2012-2016 compared to 181 cases in period 1957-1961 (Figure 3). The incidence rates 
has grown dramatically over the last decades in Norway and is predicted to rise further by 57% in 
2025 compared with the rated observed in 2005 (8).  
Registry based data usually provide incidence rates of EC that are recorded within the large 
general group “uterine cancer” (International Classification of Diseases [ICD] code C54), which 
consists of epithelial, mesenchymal and mixed tumors. Consequently, the crude number of EC 
could be lower than reported. However, sarcomas, which comprise 3-9% of all uterine cancers in 
Norway (9, 10), have had a relatively stable incidence during the last 40 years (0.3-0.4 per 100 
000/year)(11). This proves that observed increase of incidence rates of uterine cancer is mainly 




Figure 3. Incidence, mortality and survival rate in cancer corpus uteri per 100 000 person-years in Norway 1965-
2016. 
Illustration used with permission, copyright 2017 by Cancer Registry of Norway 
 
Mortality, five-year survival rate and prognosis 
In terms of mortality, the rate for EC in Norway in 2015 was 2.3 per 100 000 accounting for 67 
cases (7). The overall prognosis of EC is considered to be good as the symptoms appear at early 
stage and lead to detection of this malignancy earlier. Ward et al. (12) showed that during 5 years 
after diagnosis, 42 % women diagnosed with low grade localized EC will most likely die from 
cardiovascular disease, than from cancer (7.2%). In contrast, those who are diagnosed with high 
grade advanced EC will most likely die from this malignancy regardless of age (56%) compared to 
cardiovascular causes (15.1%). The same study showed that, when looking at 5-year interval from 
diagnosis, EC is the most frequent cause of death during the first 5 years, but then, cardiovascular 




Figure 4. Cumulative mortality rates in patients with endometrial cancer due to cardiovascular causes, other 
malignancies and other causes. 
Illustration used with permission, copyright 2012 by Elsevier Limited 
 
The five-year total relative survival (for all EC patients combined) in Norway is considered 
to be high and accounted for 84% in 2012-2016. The increase in total survival is mostly accounted 
by improvements in survival of localized disease (Figure 5). This could be partly explained by more 
successful detection of patients with metastatic lymph nodes and as a result, more frequent 
performance of staging lymphadenectomies. However, at the same time, favorable survival at early 
stages of EC could cause onset confounding taking in account that some tumors are diagnosed at 
early stage would not progress further. For advanced stages with regional and distant spreading of 
metastasis prognosis is less favorable, where the five-year survival rates decrease to 61% and 38% 
respectively (Norwegian data, Figure 5).   
International Federation of Obstetrics and Gynecology (FIGO) using its own staging system, 
defines the following distribution of 5-year survival: 85% for stage I, 75% for stage II, 45% for 
stage III and 25% for stage IV (9). However, age, histological subtype, grade and surgical stage 
have a huge impact on variation of survival rates (13). Thus, due to heterogeneous pathology 5-year 
survival vary from 92% to 42% (14) for stage I and from 68% to 17% if there is regional spread or 
distant disease (15). It is well established, that patients with type II EC has lower survival rates 




Figure 5. Five-year relative survival (%) for uterine cancer according to primary site and period of diagnosis 
(1977-2016). 
Adapted with permission, copyright 2017 by Cancer Registry of Norway 
 
1.1.2 Clinical features and diagnosis 
Clinical presentation and preoperative diagnostics 
Around 90% of EC patients have reported abnormal vaginal bleeding, which is considered to be the 
first classical presenting symptom of cancer uteri in postmenopausal women (16). For 
premenopausal women intermenstrual bleeding or menorrhagia are the most common first clinical 
signs of EC. The physicians should be aware of uterine bleeding especially in postmenopausal 
women until other reasons excluding EC are confirmed. Abnormal vaginal bleeding accounts for 5-
10% postmenopausal EC cases (16) and only 0.33% for premenopausal EC cases (17), although the 
chancing of getting EC are increasing with age. Both pre- and postmenopausal women presented 
with abdominal bleeding should be particularly examined if they have additional risk factors such as 
obesity, diabetes, menopausal hormone therapy (MHT) or tamoxifen use. Other warning symptoms 
can be increased vaginal discharge, abdominal pain and distention.  
Preoperative diagnostic is based on evaluation of such parameters as histopathological 
subtype, estimation of the myometrial infiltration depth and potential infiltration into the cervical 
stroma and other organs. The first diagnostic steps include gynecological examination, vaginal 
ultrasound with endometrial thickness >3 mm as a suggested cut-off (18) and investigation of 
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histological samples obtained either by Pipelle de Cornier curettage device or a classic fractional 
dilatation and curettage (D&C)(19).  
Preoperative histopathological diagnosis could be very challenging due to the difficulties in 
distinguishing the difference between endometrial hyperplasia (endometrial precancer) and already 
early stage of endometrial adenocarcinoma. The most challenging samples are those obtained from 
endometrial polyps and secretory endometrium. Moreover, there is still low reproducibility and 
inter- and intraobserver variation among pathologists (20, 21). At the present time, several risk 
scoring classification systems are available now for risk assessment of developing of EC from 
endometrial hyperplasia. Among them is D-score, method based on morphometry taking into 
account following prognostic criteria: the volume percentage of stroma, the standard deviation of 
the shortest nuclear axis and the outer surface density of the glands (22). 
The next step in EC diagnostics is pelvic magnetic resonance imaging (MRI) that is used for 
measuring the tumor size and assessment of myometrial invasion. Finally, computed tomography 
(CT) or X-ray examination could be used for revealing intra-or extra-abdominal spread. 
 
Treatment guidelines  
During the last 20 years essential steps were made in cancer treatment strategies, moving from 
traditional “killing paradigm” based on eradicating the primary tumor towards more “personalize 
targeted therapy”, which is aimed to select the therapy suitable for each individual patient. In 
Norway hysterectomy usually in combination with bilateral salpingoophorectomy with or without 
lympadenectomy has been used as a standard treatment of EC for surgical treatment (23, 24). 
Debulking surgery is recommended for advanced stages (24). For non-endometrioid subtypes (clear 
cell and serous endometrial carcinomas) and for carcinosarcomas it is also recommended in 
addition to perform omentecomy and lymphatic dissection (25, 26). 
Lymphadenectomy, both pelvic and para-aortic, are still recommended for complete surgical 
2009 staging, however, performing of these procedure in women with low grade and early stage 
disease, is still controversial and one of the most debated issues. Thus, several randomized 
controlled trials showed that lymphadectomy could statistically significantly improve surgical 
staging but did not bring any benefit for disease-free or overall survival both at stage I and in 
patients with higher-stage disease (27, 28). Moreover, recent review concluded that there is an 
evidence of increased surgery-related systemic morbidity or lymphoedema/lymphocyst formation in 
women who received lymphadenectomy (29). In Norway, where the rates of lymphoadenoectomy 
are higher compared to other European countries, it is recommended to evaluate DNA ploidy from 
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sampled lymph nodes and then to perform pelvic and para-aortic lymphadenectomy in patients with 
presumed high-risk tumors (24). Investigation of parameters that might help to select the patients 
with low risk of lymph-node metastasis takes one of the leading places among studies evaluating 
preoperative risk of EC. These studies showed that loss of ER/PR expression in curettage specimens 
is connected to increase risk of lymph node metastasis (30, 31). Another study reported that having 
endometrioid subtype of tumor with no evidence of deep myometrial infiltration, enlarged lymph 
nodes or distant metastasis on MRI along with serum CA125 levels < 35 U/mL is connected to 97% 
negative predictive value for detection of lymph node metastasis (32). 
Adjuvant therapy is meant to treat lymph node regions that might contain spread of 
metastasis in order to avoid the recurrence of EC. Based on the Norwegian guidelines, for FIGO 
stage I, the risk of recurrence of disease is classified into low, medium and high risk and depends on 
histological subtype (24). The patients are considered of being at high risk of recurrence if they 
have FIGO stage II or higher (24). Many of other European centers use a refines risk stratification 
system suggested by The European Society for Medical Oncology (ESMO). This approach also 
includes evaluating of various histopathological factors like lymphovascular space invasion (LVSI) 
for selecting patients for adjuvant therapy (15). Due to the lack of evidence of efficacy the 
principles for optimal adjuvant therapy for high-risk EC patients are still controversial and on 
debates. In Norway, adjuvant chemotherapy based on combined regimen of carboplatin and 
paclitaxel (TC) or paclitaxel, epirubicin and carboplatin (TEC) is commonly used for high-risk 
patients. For low risk women with FIGO stage 1A and grade 1 and 2 adjuvant radiation can be used. 
Further, adjuvant radiation in form of brachytherapy or external beam radiation is still used for 
treatment of intermediate-high risk patients in many countries (15), although in other centers this 
type of treatments is almost replaced by chemotherapy (33). However, there are ongoing clinical 
trials PORTEC-3 and GOC-258 that investigate the effect of combination of chemotherapy (CT) 
and beam radiotherapy (RT) in high-risk patients and recently reported the first results, showing the 
possible benefit of combined CT/RT in high-risk patients (34).  
 Hormone therapy is still one of the treatment options for patients with low risk of EC, who 
wish to preserve fertility and for those with advanced disease, who are not eligible for other types of 
treatment (35, 36). 
After treatment, EC patients have three to five years until recurrence of disease is diagnosed. 
The recurrence rates for patients with low, intermediate and high risk are reported to be 5-10%, 15-
20% and more than 30% respectively (37). For non-endomerioid tumours the recurrence rates are 
somewhat higher, up to 50% (38).The recurrences are usually treated with surgery, chemotherapy, 




1.1.3 Histopathological features 
Histopathology 
In classification provided by World Health Organization, endometrioid adenocarcinoma represent 
the most common subtype, which comprises 75-80% of all EC cases (40). This EC type is well-
differentiated cancer with preserved glandular architecture, lack of intervening stroma and is known 
to arise from endometrial hyperplasia (Figure 6A)(40). Other histological subtypes are combined 
into a of group of non-endometrioid cancers and consist of mucinous carcinoma (9% of cases, 
Figure 6B), serous carcinomas (3-10% of cases, Figure 6C), clear cell carcinomas (CC) (2-3% of 
cases, Figure 6D) and undifferentiated carcinomas (41). These less common non-endometrioid 
subtypes account for 20 % of EC diagnosis and are usually found in atrophic endometrium with no 
obvious precursor lesion (15, 40). Further, if two histological subtypes are present in tumor, 
endometrial carcinomas are defined as mixed if among these two subtypes at least one is non-
endometrioid tumor, presented in more than 10% of lesion (42). The knowledge and accurate 
assessment of different histological subtypes is one of the crucial components in assessment of EC 
risk and patient outcome. In contrast to well-established agreement in histological subtypes of 
ovarian cancer, EC still has a lot of disagreements and huge heterogeneity in both of diagnostic 




Figure 6. Histological classification of EC. (A) Endometrioid adenocarcinoma. (B) Mucinous adenocarcinoma. (C) 
Serous adenocarcinoma. (D) Clear cell adenocarcinoma. 
Illustration used with permission, copyright 2003 by IARC Press 
 
FIGO grade and stage 
The grading of EC tumors are performed histologically using either a 3-tiered FIGO system or a 2-
tiered (binary) systems. The FIGO grading system is based on architecture, i.e. percentage of solid 
(non-squamous) growth and cytologic atypia (40). Thus, the grade 1 tumor defines as a well-
differentiated tumors with a glandular pattern and ≤5% of solid growth, grade 2 has 6-50% and 
grade 3 more than 50% of solid growth pattern respectively. Cytologic (nuclear) atypia could 
change architectural grading through increasing from grade 1 to 2 or from grade 2 to 3. Based on a 
binary grading system, grade 1-2 and grade 3 are often transformed into low grade and high grade, 
respectively. Even though, this grading system is currently not used in clinical practice, it showed 
less interobserver variability and better prognostic power (47-50).  
 
Staging of EC 
Two surgical-pathological staging system has been used for dividing the extent of uterine cancer 
growth into stages. One is classical TNM classification, which is mainted by the UICC (51). In this 
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classification, T represents the size of the tumor and spread to nearby tissues, N represents the 
number, size and localization of lymph node metastasis and M tells about distant metastasis. 
However, for EC historically FIGO staging system has been more frequent applied since 1988 (52). 
Based on the updated and more available knowledge about risk factors related to tumor behavior 
and survival, the new version of FIGO staging was introduced in 2009. In this last updated version, 
the accurate determination of depth myometrial invasion and cervical stromal involvement is crucial 
for dividing EC into 4 stages (Table 1), although pathological assessment of myometrial invasion 
can be also challenging (53). 
 
Table 1. FIGO 2009 staging system for endometrial cancer. 
Stage I Tumor within corpus uteri 
IA Minimal myometrial invasion (no or less than half) 
IB Myometrial invasion equal to or more than half of the myometrium 
Stage II Tumor invades further to the cervical stroma, but does not extend beyond 
the uterus 
Stage III Local and/or regional spread of tumor 
IIIA Tumor invades the serosa of the corpus uteri and/or adnexas 
IIIB Vaginal and/or parametrial involvement 
IIIC1 Positive pelvic lymph nodes 
IIIC2 Positive para-aortic lymph nodes with or without positive pelvic lymph 
nodes 
Stage IV Tumor invades bladder and/or bowel mucosa and/or distant metastases 
IVA Tumor invades bladder and/or bowel mucosa 
IVB Distant metastases, including intra-abdominal metastases and/or inguinal 
lymph nodes 
 
Management of EC in regard to some histopathological factors.  
As it was mentioned before, risk estimates and treatment management of EC depends on many 
factors such as age, stage, grade, lymphovascular invasion and histological subtype. Women 
younger than 60 with endometrioid type, FIGO I stage, grade 1 or 2, myometrial infiltration less 
than 50% and without lymph vascular space invasion are associated with low risk getting 
metastasis, and no adjuvant therapy is recommended. Myometrial cancer infiltration with more than 
50% is generally linked to lymph node metastasis and associated with poor survival independently 
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of FIGO stage and histological type (54). Patients that have EC grade 1 or 2, endometrioid 
adenocarcinoma, mixed endometrioid and mucinous carcinoma are associated with favorable 
prognosis and in most of the cases are treated by simple hysterectomy (55). On contrary, grade 3 
endometrioid, serous and clear cell carcinomas are associated with disproportionate number of 
deaths. Non-endometrioid subtypes (clear cell and serous) are considered to be high-grade by 
definition irrespective of growth pattern and cytologic atypia due to the property for spreading 
outside of the uterus early in the disease process (13). Serous adenocarcinoma is known for its 
aggressive behavior due to the fast development of deep myometrial and extensive lymphatic 
invasion, so that patients have extrauterine spread already at the time of diagnosis (56). Moreover, 
this cancer type is known for its frequent recurrence and a fatal outcome. Clear-cell carcinoma is 
considered to have a poor prognosis, because most of the cases are diagnosed in advanced clinical 
stages (56), however, if clear cell adenocarcinoma limited to the uterus, than the patient has better 
prognosis than one with serous subtype of the same stage (40). In general, it has been shown by 
other studies, that within this “group of subtypes with poor prognosis” patients with grade 3 
endometrioid or clear cell carcinomas has more favorable prognosis than patients with serous 
carcinomas (44).  When it comes to the histotype-spesific treatment strategies, it has been suggested 
that for those non-endometrioid subtypes with a tendency to intraperitoneal spread it is better to use 
chemotherapy in contrast to historical radiation therapy that is used for extensive intrauterine as 
well as extant disease in EC (56). In addition, non-endometrioid subtypes along with 
carcinosarcomas usually require omentectomy due to the increased risk of intra-abdominal spread 
(25, 26).   
 
1.1.4 Molecular alterations 
Genetic changes are one of the main driving forces behind malignant transformation of a cell. At 
present, a wide variety of genetic alterations have been demonstrated to contribute to EC development 
and progression. Since the publication of Bokhman’s work in 1983, where he distinguished two types 
of EC based on clinicopathological features of tumors (Table 2) (57), many attempts have been made 
in order to fit various molecular genetic alterations into the model (Figure 7) (58). 
Nevertheless, Bokhman’s classification has never been used for the staging and risk 
assessment of endometrial tumors in clinical settings mostly due to its oversimplicity (i.e. existence 
of significant overlap between Type I and Type II tumors, high heterogeneity of tumors resulting in 
diagnostic difficulties even for experienced pathologists, etc.). Therefore, there is a need in modern 
clinically relevant classification of molecular alterations in EC which could be a reliable instrument 
in the assessment and prognosis of tumor development. 
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At present, a variety of genes are known to possess altered expression in different components 
of EC tumorigenesis (Figure 7). Among the most frequently perturbed genes in EC are PTEN (59), 
PIK3CA (60), KRAS (61), β-catenin (62), p53 (63), p16 (64), HER2/neu (65), ARID1A (66), etc. 
However, there is no pathognomonicity in a singular genetic change and particular type of EC, hence 
trends in changes of groups of genes should be considered for the appropriate staging and 
stratification of tumors. 
 
Table 2. Classification of EC into two types 
 Type I Type II 
Clinical, endocrinological, 
and morphological components 
Distribution 60–70% 30–40% 
Reproductive function Decreased No disturbances 
Onset of menopause After age 50 years Younger than age 50 years 
Background endometrium Hyperplasia Atrophy 
Oestrogen associated Yes No 
Associated obesity, hyperlipidaemia, and 
diabetes mellitus 
Yes No 
Tumour grade Low (grades 1–2) High (grade 3) 
Myometrial invasion Superficial Deep 
Potential for lymphogenic metastatic spread Low High 
Prognosis Favourable Unfavourable 
Sensitivity to progestagens High Low 
Outcome (5-year survival) 86% 59% 
Clinicopathological and molecular correlates 
Prototypical histological type Endometrioid Serous 
Oestrogen-receptor or progesterone-receptor 
expression 
High Low 
Stage at diagnosis Early (FIGO stage I–
II) 






Figure 7. Genetic alterations in EC. 
Adapted with permission, copyright 2012 by Springer Nature 
In 2013, The Cancer Genome Atlas Research (TCGA) Network proposed a novel integrated 
genomic classification of EC (67). Using multiomics approach, ECs were classified into 4 genomic 
classes:  
1. POLE ultramutated. Tumors with very high mutation rates and hotspot mutations in the 
exonuclease domain of POLE (a subunit of DNA polymerase ɛ that has a role in DNA 
replication), few copy-number aberrations, high frequency of C>A transversions, mutations 
in PIK3CA, PTEN, PIK3R1, FBXW7, and KRAS genes, and favourable outcome. 
2. Microsatellite instability hypermutated. Tumors characterised by microsatellite instability 
due to predominantly MLH1 promoter methylation, high mutation rates, few copy-number 
aberrations, KRAS and PTEN mutations. 
3. Copy-number low. Microsatellite-stable grade 1 and 2 tumors with low mutation rates, 
exhibiting increased frequency of CTNNB1 mutations 
4. Copy-number high. Tumors, demonstrating abundant copy-number aberrations and low 
mutation rates, increased number of TP53, FBXW7, and PPP2R1A mutations, rare PTEN 
and KRAS mutations, and poor outcome. 
The high clinical potential of this classification has been validated in numerous studies (68). 
However, the high cost of the laboratory techniques used by TCGA hampers the implementation of 
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the classification into clinical practice, therefore combination of existing tools (IHC, FISH, etc.) and 
omics analysis should be further considered.  
 
1.1.5 Established risk factors  
Numerous risk factors that account for EC development have been described up to date (23). In this 
thesis, I will mainly focus on age, age at menopause, age at menarche, cumulative number of years 
of menstruation, obesity, pregnancy and parity/nulliparity, breastfeeding, oral contraceptive (OC) 
use, MHT, diabetes mellitus, physical activity and coffee consumption.  
 
Age   
EC is still a disease of elderly women with the mean debut age at 50 years. Higher age at diagnosis 
is considered to be an important prognostic factor in terms of lower survival rates and increased 
mortality, although it could be partly explained by the fact that elderly patients in general develop 
more aggressive histological subtypes, and in addition get less aggressive therapy due to more 
frequent complications. EC is also described in women younger than 35 years (51) and even in 
teenagers (69). In Norway the increasing of age-spesific incidence rate is observed between in age 
45 and 70 with a peak at age period 75-79 (Figure 8). 
 
Exogenous Hormonal Risk Factors in EC 
OC 
Since its introduction in 1960, combined oral contraceptives (COC) has gained both widest 
geographic distribution and undergone substantial evolution in hormone formulations and doses. 
Nowadays, COC represents the most common modern contraceptive method in developed countries 
and third most common in developing countries (70, 71). Apart of effective protection of 
unintended pregnancy, COC account for improvement in menstrual bleeding, reduction in risk of 
iron deficiency anemia and ectopic pregnancy, protection against some cancer types and other 
beneficial effects (Figure 9) (72). However, some adverse effects such as increased risk for cardio-
vascular events (thrombosis, stroke) and risk for cervical and breast cancer (BC) are well-known, 




Figure 8. Age-specific incidence rates of uterine cancer per 100 000 person years and five-year age group, in 
Norway during the period 2012-2016. 
Adapted with permission, copyright 2017 by Cancer Registry of Norway 
  
 
Figure 9. Non-contraceptive benefits and risks of oral contraceptive use 





The beneficial lasting protective effect of OC use in regard to EC is well-established by 
numerous studies (74). The risk of EC is almost halved with the use of OC and the reduction effect 
comes first 2-5 years after use. It has been also shown, that the risk reduction is directly related to 
the duration of OC use and remains minimum 15-20 years after the end of use. Population-based 
case-control study from Danmark in 2000 showed that OC use in 1-5 years reduce the risk of EC in 
women under 50 years (OR 0.2; 95% CI 0.1-0.3) (75). Another study from Sweden reported a 
decreasing trend for EC risk med increasing duration of OC use (76). There were no association 
with OC use and EC risk if the duration of OC use was under 3 years. While, three and more years 
of OC use gave the risk reduction with OR0.5 (CI 95% 0.3-0.7). Halving of risk of getting EC 
during the next 20 years due to OC means from 0.05% to 0.03% risk reduction for 25 years women, 
and from 0.16% to 0.08% risk reduction for 30 years old women (77). Later on, the collaborative 
Groups’ analysis of 36 epidemiological studies that reported their findings between 1987 and 2004 
confirm the evidence that OC prevent EC and has a long-term protection (Figure 10) (78). Every 5 
years of use was associated with a risk ratio of 0.76 (95% CI 0.73–0.78; p<0.0001) with more risk 
reduction for carcinomas than sarcomas. The risk reduction persisted for more than 30 years after 
the last OC pill was used, showing no apparent decrease between the RRs for use during the 1960s, 
1970s, and 1980s, despite higher estrogen doses in pills used in the early years (78).This study 
claims that OC use conferred long-term protection and about 400 000 cases of EC before age 75 




Figure 10. Relative risk of endometrial cancer in users of oral contraceptives by duration of use and time since last 
use of oral contraceptives. 
Illustration used with permission, copyright 2012 by Elsevier Limited 
  
The exact mechanisms by which OC reveals protective effect on endometrium especially 
many years after cessation remain unclear. The most discussed hypothesis proposes that those 
women who use continuous COC have fewer days of unopposed estrogen exposure period every 
month (79). It is indeed known, that mitotic activity rates in endometrial cells are lower during first 
four days of  menstrual cycle, then increase rapidly and remain steady up to day 19, and finally, 
drop to zero for the rest of the cycle period (80). In addition to shorten of period with unopposed 
estrogen exposure, a synthetic progesterone also is believed to contribute to protective effect on 
endometrium (81). 
 
Menopause Hormone Therapy (MHT) 
Since 1940s when the first MHT preparation, Premarin, came to the market, many changings have 
been done in the formulation of MHT. The first introduced hormone therapy was based on estrogen 
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only and has been produced to provide a relief for menopausal symptoms and in addition, prevent 
many of adverse effects of aging.  However, later it was shown that those women who received 
menopausal unopposed estrogen therapy have a substantial increased risk of EC (82). Several case-
control and prospective studies confirmed an increasing risk of EC due to long-term use of 
unopposed estrogen, and relative risk (RR) varied from 3.1 up to 15 (83, 84). First analogue reports 
led to decline in use of estrogens preparations (85) and initiated the changings in MHT’s 
formulations in form of adding progestin in order to minimize the proliferative effect on 
endometrium (86). The results from the Million Women Study showed later that those who 
currently used estrogen only therapy had a 50% increased risk and users of tibolone preparations 
had 80% of increased risk (87). The same study showed that risk was lower in women with a body 
mass index (BMI) < 25 compared to those who had BMI >= 25. Moreover, it has been shown that 
the risk of endometrial hyperplasia, precursor of EC, is not reduced if unopposed estrogen is given 
in a cyclic regimen (88). Later coming reports indicate that EC risk could be substantially decreased 
by MHT with progestin given in either a cyclic or continuous regimen (89), however, it has been 
also shown monthly users of estrogen-progestin MHT in cyclic regime are at higher risk of 
developing EC compared to those who use this type of MHT in continuous regime (90).  
 
Endogenous Hormonal Risk Factors in EC 
Reproductive Risk Factors 
High levels of endogenous estrogens increases the risk of EC via increasing of mitotic activity of 
endometrial cells (91). On the contrary, progesterone, can slow down this mitotic activity induced 
by estrogen and promote differentiation of epithelial cells making them less susceptible to 
malignant change (92). Each pregnancy is a unique health condition associated with addition 
intense progesterone production, which compensates stimulating effect of estrogen on mitotic 
activity in endometrium and, therefore, protects against EC development (93). Over several 
decades, numerous studies have demonstrated that in comparison to nulliparous women, parous 
women have decreased risk of developing EC. This was showed by both case-controls (94-96) and 
prospective studies (97, 98). The last updated pooled-analysis from 2015, including 10 prospective, 
35 case-control studies and 1 pooled analysis of 10 cohort and 14 case-controls studies, where the 
final sample size comprised 69 681 patients, revealed a significant inverse association between 
parity and EC risk with RR 0.69, 95% confidence interval (CI) 0.65–0.74; I2=76.9%) (99). Further, 
dose-response analysis from this study showed a nonlinear relationship between the number of 
parity and EC risk. Another non-hormonal mechanism that is believed to have a role in association 
between EC and parity, is connected to mechanical clearing of uterus lining from precancerous cells 
27 
 
that have undergone malignant transformation (100, 101). This theory has raised based on the 
findings that revealed that later age at last birth is associated with lower EC risks. Indeed, one of the 
last pooled analyses showed that in comparison to women who had their last child after 25 years, 
those who gave birth of their last child after 40 years had a 44% lower risk of EC (OR = 0.56, 95% 
CI: 0.47, 0.66). They also showed a linear decline in EC risk within increasing of age at last birth 
and 13% decrease in EC per 5-year delay in last birth (102).  
The studies investigating the relationship between miscarriages and abortions in relation to 
EC development have been less conclusive. Some of the studies showed a protective effect (103), 
however, others could not find any association (104). The possible explanation of mechanisms 
involved in this association is very poor described in the literature. It was hypothesized that 
pregnancies that ended before the gestational age of 22 weeks could increase the risk of BC due to 
increased estrogen level and relatively low progesterone level at this time of pregnancy. This could 
provoke BC cells to grow in the light of future lactation, and then, in case of early ending of 
pregnancy, keep these undifferentiated cells. Interestingly, this hypothesis is still up to present time 
have not been applied to EC (105). The findings regarding provoked abortions and risk of EC are 
also quite contentious, showing positive (106), negative (107) and null association (98).  
 
Breastfeeding  
Breastfeeding is believed to cause protective effect against developing EC through suppression of 
gonadotrophin-releasing hormone following suppression of ovulation, decreasing circulating 
estrogen levels and increasing of progesterone levels.  
First findings connected to the association between EC and breastfeeding have been for along time 
inconclusive and inconsistent (108). Most of the previous studies reported inverse association (109), 
however, there were some reports that could confirm this finding (98). Recent meta-analyses from 
the Epidemiology and Endometrial cancer consortium showed that ever breastfeeding gives a 11% 
reduction in EC risk (pooled OR 0.89, 95% CI 0.81–0.98) and longer duration of breastfeeding is 
associated with lower EC risk (110). Moreover, this study showed that the protective effect of 
breastfeeding lasts during the first 6-9 months of lactation period. According to some studies, it 
could be explained by additional effect of suckling stimulus that contributes to lowest levels of 






Menstrual Risk Factors  
Age at menarche and age at menopause are the two most frequently studied risk factors in hormone 
dependent conditions including EC. Table 3 gives a brief overview for some of these studies.  
 
Table 3. The risk of EC in relation to early menarche and late menopause 
Author, year Study type Indicators Type of 
measurement 
Increase or decrease in risk 
Brinton et al, 1992 
(104) 
Case-control study Early menarche Relative Risk 2.4 risk increase for age <12 vs ≥15 y 
Reis and Beji, 
2009 (112)  
Case-control study Early menarche Odds ratio 9.43 vs later age of menarche 
Zucchetto et al, 
2009 (113) 
Case-control study Late menarche 
Late menopause 
Odds ratio 0.7 decreased risk for ≥14 vs <12 y 
1.8 decreased risk for age ≥ 55 vs < 50 years 
Dossus et al, 2010 Prospective study Late menarche 
Early menopause 
Relative risk 7%-8% decreased risk 
7%-8% decreased risk 
Reproduced with permission from (114). 
 
Link between late-age menarche, early-age menopause to decreased EC risk, along with 
association between early-age menarche, late-age menopause and increased EC risk are based on 
lifetime exposure to estrogens and number of menstrual cycles/number of menstruations women 
experience during the life. Older age at menarche is associated with a shortening of menstruation 
span and decreased risk of EC due to later initiation of ovulatory cycles and start of excessive 
exposure to estrogens. The recent dose-response meta-analysis has shown a 4% risk reduction for 
per 2 years delay in age of menarche (115). At the same time, later age at menopause can prolong 
the lifetime of menstrual activity and exposure to estrogens, and therefore increase EC risk. 
Relationship between EC risk and these two variables could be also confirmed by reciprocal 
association of age of menarche and age at menarche: the effect of later menopause can be attenuated 
by later age of menarche and on contrary, the effect of earlier menarche can be attenuated by earlier 
menopause (105). Several studies aimed to show the link between the number of menstrual 







Table 4. The risk of EC in relation to number of years of menstruation and lifetime number of menstrual cycles 





Wang et al, 2015 (116) Case-control 
study 
Odds ratio TNMC-Total number of menstrual 
cycles 
≤ 424                    1.00 (ref) 
> 424               1.40 (1.01-1.95) 





Odds ratio Index of anovulation (years 
without ovulation) 
≤ 26                       1.00 (ref) 
27–59               0.25(0.12–0.53) 
60–104             0.22(0.11–0.46) 
≥ 105                0.17(0.08-0.35) 




Odds ratio Years of menstruation <33                       1.00 (ref) 
33-36                1.63(1.15-2.29) 
>37                  2.43 (1.72-3.44) 




Odds ratio Menstruation span (number of 
years of menstruation) 
For women <70 years 
<25                          1.00 (ref) 
25-29                     1.4 (0.5-4.1) 
30-34                   2.61.(1.0-6.9) 
35-39                   4.5 (1.7-12.0) 
40+                      4.7 (1.4-15.9) 




Odds ratio Years of menstruation < 30                        1.00 (ref) 
30+                     1.3(0.95-1.78) 
35+                     1.93(1.38-2.7) 
40+                        2.7 (1.7-4.4) 
Yang et al, 2016 (118) Case-control 
study 
Odds ratio Lifetime number of ovulatory 
cycles 
196.3-402               1.00 (ref) 
403-444.5           1.3(0.85-2.00) 
444.6-479.9        1.5(0.92-2.42) 
480-602.3          1.9 (1.11-3.44) 




Odds ratio Years of fertile life < 31                         1.00 (ref)  
31-35               1.02 (0.35-2.99)  
36-40               1.21 (0.45-3.23)  
> 40                 0.89 (0.24-3,28)   







Cohort Relative risk Years of ovulation ≤ 33                      1.00 (ref) 
33.01-36.25     1.25 (0.76-2.09) 
36.26-38.25     2.00 (1.21-3.31) 
38.26-40.50     2.84 (1.74-4.62)  
>40.50             3.63 (2.21-5.95) 
 




Wermli et al, 2006 (120) Cohort Hazard ratio Menstruation span <30                       1.00 (ref) 
30-34               1.47 (1.01-2.14) 
35-39               2.69 (1.01-2.14) 
40-44               9.25 (2.88-29.7) 
 
BMI 
Excess body weight and obesity became a major challenge for public health (121). During the past 
four decades, the prevalence of obesity among women has more than doubled (122). In Norway the 
increasing of obesity is also observed which account for 20% of adult population (123). Increasing 
obesity epidemic contributed to increase of EC incidence rates specially in the Western World, 
although the lay public awareness and knowledge to this problem is shown to be limited (124). It 
has been shown, that obese women may have up to 6-fold higher EC risk compared to lean woman 
(125), and that association between BMI and EC in Europe is significantly stronger than in regard 
to most other cancer types (126). Crosbie and colleagues in their meta-analysis (127) reported that 
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effect of BMI is non-linear and those women who had BMI higher than 42 kg/m2 had a 9.11 greater 
risk of developing EC compared to women with BMI 22 kg/m2. Million Women Study (128) found 
a significant positive trend in the RR of incidence with BMI for EC (RR per 10 unit increase in 
BMI=2.89, 95% confidence interval 2.62 to 3.18). Studies investigation association between obesity 
and EC risk separately for pre-and postmenopausal women found higher risk for older women. 
Bjørge et al in their study of Norwegian women found the most pronounced effect of BMI 
(especially high BMI) in older age group (129). 
The mechanisms lying behind the association between obesity and EC are linked to the 
following processes (130): 
● excess estrogen production due to aromatization of androgens into proproliferative 
estrogens; 
● direct mitogenic effect of estrogens produced from adipose tissue, which is not 
counterbalanced by progesterone due to reduced progesterone production in the light 
of chronic anovulation; this is considered to be the predominant determinant in 
pathogenesis of EC in obese premenopausal women (125); 
● increase in local production of the mitogens insulin and IGF-1 (both are endometrial 
growth factors) through a reduction in insulin sensitivity; 
● inhibited production of sex-hormone binding globulin (due to increased insulin level) 
that causes increase the levels of active estrogen; 
● chronic release of high levels of inflammatory mediators; 
● production of cytokines (leptin and adiponectin) in fat tissue that take part in 
endometrial carcinogenesis (115, 131); 
● effect of transcription factors that regulate both tumorigenesis and cellular lipid 
metabolism (132);  
However, several studies suggested that the mechanisms linked to obesity and endometrial 
canser risk development are different in pre- and postmenopausal women. In premenopausal 
women obesity is associated with anovulatory cycles and through this mechanism is associated with 
increased EC risk (133). In contrast, postmenopausal women with generally a lower oestrogen 
levels compared to premenopausal women, have adipose tissue as a primary source of endogenous 
E2. Thus, it is suggested that in these women the rate of production of circulating oestrogen is 
related to the size of the adipose depots (125). Summary of pathways involved in association 




Figure 11. Pathways involved in association between obesity with endometrial cancer development. 
Illustration used with permission, copyright 2012 by Elsevier Limited 
 
Other acquired or life-style factors 
Smoking 
Numerous epidemiological studies have been evaluated the association between cigarette smoking 
and risk of EC, showing an inverse association among ever smokers and somewhat stronger 
protective effect in current smokers compared to former smokers (134). Moreover, it has been 
shown that protective effect remains after cessation, if it occurs 1-4 years prior to EC diagnosis 
(134).  
There are several anti-estrogenic mechanisms through which smoking can protect against EC: 
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● cigarette smokers are as usual leaner compared to non-smokers and thus potentially has less 
adipose tissue that is known to be an additional source of estrogens;  
● smoking can decrease  estrogen-derived cellular proliferation of endometrial cells through 
increasing of 2-hydroxylation of estradiol, increasing androgen levels (135) and by slowing 
down the decay of progesterone (136); 
● direct destructive toxic effect of smoking on the oocytes (137), reducing number of ovarian 
follicles causing earlier menopause (138);  
Remarkable, smoking has a unique ability to attenuate the effect of endogenous and exogenous 
hormones on endometrial carcinogenesis. Several studies reported that menopausal status plays an 
important role in association of EC and smoking, revealing reduction in EC risk in postmenopausal 
women and no association or even increased risk in premenopausal women (139). Further, among 
current smokers, in comparison to premenopausal women, postmenopausal women have about 20% 
lower estriol excretion rates (140).  It has been also demonstrated that smoking has an impact on 
level of circulating estrogens and can attenuate the effect of oral estrogens on for example bone 
density and serum lipids (141, 142). Moreover, EC risk reduction by smoking is known to be 
stronger among MPT users versus nonusers (139). 
 
Physical activity (PA) 
The known link between PA and EC is mostly based on weight control and following 
improvements in hormone metabolisms. Most of the studies investigating this association showed 
an inverse relationship with up to 22% of risk reduction associated with recreational PA (143). 
Further, numerous other studies also reported inverse association (144-147). Thus, recent findings 
from NOWAC Study showed dose-response trend in decreasing the EC risk within increasing of 
PA levels from lowest PA level giving HR=1.6 (95% CI 1.16-2.2) to highest PA level with HR 
=0.73 (95% CI 0.45-1.16) compared to the median level (148). This study showed that 21.9% of EC 
could be avoided, if women with PA level ≤ 4 in 1-10 degree scale could have instead increased 
their level of PA up to 5-10. The main area for discussion in analyzing the data based on association 
between EC risk and PA is linked to BMI, which is believed to be an important confounder 
affecting hormone profiles. However, several studies, including recently mentioned NOWAC 
Study, were able to report no significant effect modification for BMI, confirming independent effect 
of PA (144, 145, 149-151). Modifying other hormonal risk factors involved in endometrial 
carcinogenesis is another hypothesis lying behind the association between PA and EC. Thus, it was 
hypothesized that increased physical activity could contribute to later menarche and amenorrhea, 
two conditions that are linked to reduced EC risk (152). Moreover, alternative mechanism could be 
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Along with the well-known effect of unopposed estrogens, insulin resistance and enhanced 
metabolism of related growth-factors are associated with increased risk of EC. Studies investigating 
this association have reported up to 80% increased risk of EC in women with type 1 diabetes and a 
2-fold increased EC risk in individuals with type 2 diabetes (154-156). In addition, some of the 
studies pointed the importance of having diabetes in younger ages, showing a higher RR of EC that 
had diabetes at age less than 40 and 50 years old (157, 158). 
The most described changes involved in the association between diabetes and EC development are: 
● growth-enhanced properties of insulin, increased activity and levels of IGF-I receptor in 
tumor cells, caused by suppressed gene expression of endometrial IGFBP-1 (159-161).  
● insulin resistance, compensatory hyperinsulinemia and elevated levels of insulin growth 
factor cause inhibition of hepatic synthesis of sex hormone binding (SHBG) and stimulate 
ovarian synthesis of sex steroid hormones (162); 
● deregulation of fatty acid synthase activity, chronic inflammation and oxidative stress (163);  
The overview over steps of pathogenesis in relationship between cancer and diabetes is illustrated in 




Figure 12. A multi-step model of cancer development associated with insulin resistance. TG: triglycerides; FFA: free 
fatty acids; TNF-α: tumor necrosis factor α; IL-6: interleukin-6; ROS: reactive oxygen species; SHBG: sex-hormone-
binding globulin; IGF-I 
Illustration used with permission, copyright 2014 by John Wiley and Sons 
 
Nutritional risk factors and EC  
Intensive rise in EC incidence catalyzed a cascade of studies related to prevention strategies 
including investigating effect of diet. It has been hypothesized that diet independently of obesity 
may play a role of modulating of chronic inflammation which is known to be an important risk 
factor and one of the possible reasons for EC development (164). During the last decades there have 
been a numerous studies investigating different aspects of diet related to EC risk such as saturated 
fat intake (increased EC risk) (165, 166), soy/fiber products (decreased EC risk) (167) and vitamin 
supplementation (decreased risk)(168). However, according to the report from World Cancer 
Research Fund 2013 (WCRF), there is a limited evidence of association between EC risk and 
specific dietary components with exceptions on coffee consumption (protective affect) and possible 
negative association with glycemic load (169). However, recent case-control study from Italy 
reported a statistically significantly lower EC risk in women with high vegetable intake, high 
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adherence to the Mediterranean diet and low dietary inflammatory index  (170). This could be 
explained that Mediterranean diet is phytoestrogens and several antioxidants that have a protective 
effect on EC development. 
 
Coffee consumption  
Coffee is one of the most frequently consumed hot beverage in the world, which is in spite of 
known adverse effects, is more associated as a potential source of antioxidants and anti-mutagenic 
compounds. The latter attractive features of coffee have raised the interest of investigating 
association between coffee consumption and different cancer types, including EC. Since 1986, 
when the first study investigating effect of coffee on EC cancer was conducted (171), variety of 
studies with different design have address this epidemiological question and found in most of the 
reports a decreased risk of EC (171-176) (Figure 13). The RR of total consumption in two recent 
meta-analyses from 2015 and 2017 were almost identical: 0.80 (95% CI: 0.74-0.86) (177) and 0.79 
(95% CI 0.73-0.87) (178), respectively. A meta-analysis from 2015 found in addition stronger 
effect in never hormone users (RR 0.60 95% CI 0.50-0.72) and in women with BMI ≥ 25 (RR 0.57 
95% CI 0.63-0.94) along with dose-dependent relationship in caffeinated coffee, decaffeinated 
coffee and caffeine intake. Meta-analysis from 2017 has also reported a 24% EC risk reduction in 
postmenopausal women (178). 
 
Figure 13. Overview of prospective cohort studies used in meta-analysis 2015. 






1.2 Gene expression  
Gene expression in the light of central dogma of molecular biology 
Nucleus of eukaryotic cells are the unique carriers of individual set of protein-coding genes that are 
stored in DNA and determine the cell function. The central dogma of molecular biology, which was 
first introduced to the scientific world by Francis Crick, describes how a gene is ultimately 
expressed (179). Basically said, when the cell receives a command about expression of a certain 
gene RNA polymerase sticks to this actual region of DNA where this gene is located and makes a 
RNA copy of it (transcription) (Figure 14). Then, this RNA copy goes out of the cell’s nucleus and 
transfer biological information further into protein through translation process in ribosomes. This 
simply explained process of how the biological information can be transferred from DNA to RNA 
and further to protein product is actually gene expression.  
 
Figure 14. The central dogma of molecular biology. 
Illustration used with permission, copyright 2015 by Elsevier Limited 
 
Remarkably, that even though each cell nucleus contains thousands and thousands of genes, 
only a part of those genes transforms into messenger RNA (mRNA) transcripts at any given time 
and thus, produce of certain amount of a particular protein. In this context, measurement of gene 
expression level is linked to the level of abundance of mRNA produced during transcription (180). 
37 
 
Controlled and regulated production of a certain number of proteins is the basement of 
balance between synthetic (transcription, translation) and degradative (enzymatic breakdown of 
RNA transcripts and existing protein molecules) biochemical mechanisms. Control of synthetic 
mechanisms is crucial in regulating what proteins and in what amounts should be present in the 
cells. This ability allows cells to be able to adapt to changes caused by different agents in their 
environment and as a result, to change gene expression in response to exposure (for example, 
particular risk factor). 
 
Microarray technology 
The use of microarray technology allows to measure the expression of a big number of genes. In 
this thesis, the analysis of gene expression data is based on the measurements obtained from whole 
blood RNA samples, which were stored in PAXgene tubes. Generally, microarray analysis consists 
of the following basic steps (Figure 15): 
I. Construction of Microarrays 
● Preparation of probes (cDNA fragments or oligonucleotides) complimentary to a set of both 
coding and non-coding human genes (expression of approx. 20 000 genes might be tested by 
a microarray platform); 
● Spotting probes onto a solid substrate (for example, glass slides or membrane); 
II. Preparation of samples 
● Blood or tissue sample collection; 
● mRNA isolation, purification; 
● Synthesis of cDNA or cRNA from mRNA; 
● Fluorescent (in our project) or radioactive labelling of cDNA/cRNA; 
III. Hybridization 
● Hybridization (selective complementary base pairing between the study samples and probes 
on the array); 
● Washing away unbound material; 
IV. Analysis 
● Scanning by quantifying of signal intensities (mRNA abundance) using a 
chemiluminescence detector;  
● The level of expression of a certain gene correlates with intensity of the signal: the stronger 
the signal, the more expressed the gene; 
● Data analysis; 
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In this thesis, studying of blood gene expression allowed us to reveal which genes were 
activated or deactivated at the time of blood donation, and how these changes in gene expression 
were related to the association between different exposures and EC. 
 
 
Figure 15. Example of basic steps of microarray technology. 
Illustration used with permission, copyright 2014 
 
Blood as a target tissue: potential benefits and limitations 
Rapidly developing high-throughput genomic technologies expanded the opportunities for 
genotyping of large number of samples and our better understanding of different steps of 
carcinogenesis. However, using of such technologies have several limitations, included necessity to 
obtain in most of the cases a sample from a certain specific tissue. Such way of sample collecting, 
like for example, biopsy from a visceral organ could be possible in case of planned surgery or as a 
part of diagnostics in already manifested disease, otherwise, in many other cases and especially, in 
case of obtaining tissue-sample in a healthy control is difficult to perform (181).  In this context, 
collecting of peripheral blood is relatively non-invasive procedure that does not necessarily require 
hospital admittance or even attendance and could have been performed at the first level of health 
care institutions (general practitioner’s office). Moreover, being a “surrogate transport tissue” (182), 
that interacts with all other tissues in the body, peripheral blood mirrors all the physiological 
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processes connecting to both normal functioning and pathological changes in our body. Altogether, 
non-invasiveness of the sample collection process, feasibility of their use in human population 
studies and unique opportunity of blood to reflect all the physiological processes, make blood 
sampling a valuable tool for integrating the principles of basic science in modern epidemiology.  
 
“If you have cancer and you are a mouse, we can take good care of you…” 
Judah Folkman 
Performing biomedical research using murine models and cell lines, and further translation of the 
obtained results on human trials gets an increasing number of critical discussions. Although non-
human models have contributed a lot to our general understanding of pathogenesis of cancer and 
other diseases, there is still a huge significant divergence in humans and mice, for example, in terms 
of physiology, immune systems functioning and carcinogenesis (183). According to some studies 
the average rate of successful implementation of animal models in human clinical cancer trials is 
quite low and comprises less than 8% (184). Thus, developing of biobank research turned a 
biomedical research towards an alternative approach, when it became possible to develop 
preventive, diagnostic and treatment strategies based on compatible human samples. 
  
1.3 Systems epidemiology approach 
The traditional epidemiology has been built up to determine the occurrence of the disease in a 
population,  aiming detecting the higher risk symptoms by investigating the association of the 
certain exposures and diseases, and further on, developing a health improving messages to the 
public with further primary and secondary prevention strategies. The described approach, however, 
has a minimal focus on the mechanisms and sometimes almost ignores the biological background 
lying behind these associations. This phenomenon is well described as a “black box of 





Figure 16. “Black box epidemiology” phenomenon. 
Illustrations used with permission, copyright 2011, 2014 by Elsevier Limited 
 
On the contrary, classic molecular science has for a long time investigated how a specific 
single gene or a protein solely can influence a biological phenotype. Further advances in high-
throughput technologies opened a new revolutionary era of “multi-level omics approaches” and 
created new definitions for novel integrated “systems disciplines” like for example, systems biology 
(SB) (186) or recently presented systems immunology (SI) (187). Thus, SB discipline moved 
traditional molecular biology to the next step of basic science development, focusing on cellular 
signaling networks between the cells, stroma, organs, and finally, on how all these changes work in 
the entire organism. This expands our understanding, how intracellular environment of the normal 
cells is affected by carcinogenesis, and how these findings can be further implemented in 
developing of new cancer-therapy strategies and predictive models. However, this approach has 
also several limitations and among others-a minimal focus on individual life’s exposures and on 
possible normal variation of the gene expression in human based on a big large-scale population-
based data. In this context, Norwegian Women and Cancer (NOWAC) Study is a big cohort 
population-based study, that on the one hand contains a big sample size for valid estimations of 
relationship between different lifetime exposures and diseases, and on the other hand has biological 
samples that were taken during different life periods of cohort participants. Biological material 
could be further analyzed on the high dimensional gene expression level according to the available 
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exposure information and could tell us, how different risk factors affect the gene signatures in both 
those with disease (cases) and without it (controls) in doe example, nested case-control study. This 
integrated multi-level approach, already known as systems epidemiology (SE) (188) could serve as 





The overall objective of this doctoral thesis was to elucidate the effect of some of the risk factors for 
EC and to implement systems epidemiology approach to the large-scale population-based 
Norwegian Women and Cancer Study. 
More specific objectives are highlighted as following: 
● To  gain further insight into association between coffee consumption and EC risk in 
postmenopausal women within NOWAC cohort and to examine how this association 
interact with BMI (Paper I) 
● To assess the combined effect of reproductive and menstrual factors using a composite 
variable LNYM (Lifetime number of years of menstruations) and to calculate population 
attributable fraction of LNYM within NOWAC cohort (Paper II) 
● To investigate gene expression signatures in blood by direct testing of hypotheses obtained 




3. MATERIALS AND METHODS 
 
3.1 Study populations 
This thesis is based on data from prospective cohort study, the Norwegian Women and Cancer 
study (NOWAC) (Paper I and Paper II) and its subcohort – The NOWAC Postgenome Study (Paper 
III). 
 
3.1.1 The Norwegian Women and Cancer Study (NOWAC) (Paper I and Paper II) 
The Norwegian Women and Cancer (NOWAC) Study (https://site.uit.no/nowac/) was initiated in 
1991 as a study that was created initially to build up a national-based cohort that would be 
representative for the entire Norwegian female population. Such design would allow calculation of 
both RRs and attributable risks in regard to certain cancer types and exposures with a primary aim 
of investigating the relationship between OC use and BC. All the NOWAC participants were 
selected based on the random sampling of women from the Central Population Register (CPR). This 
selection was possible due CPR’s information about all women living in Norway, including those 
temporary residents, refugees etc. The availability of this information is based on the unique 
national 11-digit identity number, which is assigned to each inhabitant and is used in all official 
registers in Norway. The personal number then is transformed into a serial number by Statistics 
Norway, department that was responsible for sending the reminders to non-responders in form of a 
postcard.  
The process of enrollment of NOWAC participants is complex and consists of several waves, 
where the first recruitment period was distributed into 24 different mailings over seven years. Such 
arrangement was constructed due to logistics, financial reasons and need in methodological sub-
studies. These women who answered the first questionnaires received also invitation to fill in a 
follow-up questionnaire. In addition, in order to increase response rate, two reminders per serie 
were sent to both first and follow-up questionnaires.  The last updated version of NOWAC 
recruitment scheme representing all mailings that were sent during different periods is shown in 
Figure 17 and Figure 18. This scheme has been constructed according to sending of first, second, 
third and fourth questionnaires: 
● The red boxes represent the first or “enrollment”/“baseline “ questionnaires that have been 
sent in three main time points: 1991, 1995-1997, where of 179 388 women aged 30-70, 
102 443 agreed to participate (all together series 1-24 with a response rate 57.1 %) and 
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2003-2007 (series 35-36, 40, 41, 43-45) with a response rate 48%. Response rates were 
calculated with correction for emigration, death and unknown addresses; 
● The green boxes and yellow boxes represent the distribution of second and third 
questionnaires respectively. These “follow-up questionnaires” have been sent to the women 
that had already received questionnaires before. Depending on the planned study design, 
they had different content and were sent in different periods. Dispensation of a second 
questionnaire was started during the period 1998-2002 and were sent to those recruited in 
the first 24 mailing series (series 25-29 with response rate 81%) (189). The second wave of 
sending of these “green” follow-up questionnaires was in 2011 and 2014 and was meant for 
those women who received first “red” questionnaires in 2003 and 2004. Distribution of a 
third questionnaire started in 2001 (2001, 2003, 2004, 2005 and 2010) and completed 
some additional information for women who received both “red” and “green” 
questionnaires. Women who responded to both second and third questionnaire comprised 
80.7% (unpublished data); 
● Finally, the next round of sending of fourth questionnaires for the new participants has been 
recently started in 2017; 
As it was mentioned above, the questionnaires were designed according to the different 
purposes (research hypothesis). Moreover, they have been sent in different time points. As a 
consequence, different subgroups of NOWAC participants had a various set of information. 
During all sending rounds women received a standard letter of invitation with a short 
description of study aims (see Appendix 1 as an example of invitation letter and first enrollment 
“red” questionnaire), prove of approval from the ethical committee, approval from the legal 
right to keep data computerized (by Norwegian data inspection board) and information on right 
to be withdrawn from the study at any time. The core information presented in the first 
questionnaires was devoted to questions related to OC use (ever/never use, use before first birth, 
total duration and etc). Among general information women were also asked about age at 
menarche, menopausal status, number of children, lactation, smoking, medical history, physical 
activity and dietary intake. The later series on questionnaires varied in content and had in 
addition questions on other lifestyle factors such as sun bathing habits, HRT and medication 
use. In addition, a more detailed food frequency questionnaire (FFQ) was added in 1996. 
 
3.1.2 The NOWAC Postgenome study (Paper III) 
The NOWAC Postgenome study has been built up within the original NOWAC study (Figure 17 
and Figure 18) based on the prospective collecting of blood samples from women that already 
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participated in study and gave an informed consent for blood sampling. These women were 
randomly selected in series of 500 from the whole NOWAC Study. All potential participants 
received a folder consisting of a consent form, special tubes for blood collecting, and two-page 
questionnaire that women answered at the time of blood sampling. Those who agreed to participate, 
have been offered to perform the blood sampling in their local GP’s office. Obtained blood samples 
then were sent by ordinary mail to the NOWAC centers, where they were further prepared to be 
stored in -80 °C. Initially, as a part of collaboration with EPIC Study (190), all the blood samples 
were processed in order to preserve frozen buffy-coat samples. However, a pilot study in 2001 that 
was later conducted in NOWAC, showed that the quality of the obtained samples was insufficient in 
terms of RNA isolation and gene-expression analyses. Therefore, during the next waves of sample 
collection, which took place in period 2003-2006, all the blood samples were split in 2 aliquotes: 1 
– for plasma and buffy coat isolation  and 1 – for RNA isolation using a PaxGene Blood RNA 
System (191). The latter tube type contained a special RNA stabilizing agent, which was meant to 
improve the quality of RNA preservation. By 2006, the blood sample collection comprises 48 943 
women born between 1943 and 1957, and became a baseline for core postgenome cohort (blood 
drops in Figure 17 and Figure 18).  
 
3.2 Ethical approval 
All the studies included in this thesis are based on informed written consent from each participant in 
NOWAC Study and performed in compliance with the Declaration of Helsinki. The information on 
cancer diagnosis is obtained by Statistic of Norway via linkage to the Cancer Registry of Norway, 
which delivers further the information to researchers using the serial number instead of original 
identity number. Women participated in NOWAC Study were informed about these linkages. In 
addition, those women who donated blood samples were informed that the blood samples would be 
used for gene expression analyses. In accordance with the Norwegian Biobank Act, the studies 
based on gene expression analysis were approved by the Regional Committee for Medical and 
Health Research Ethics (REK Nord) and the Norwegian Data Inspectorate (REK number for the 
biobank in NOWAC 141/2008, REK number for the study described in paper III-2012/413). 
 
Some general issues concerning study sample used in the papers 
Due to a variety of information used in the current thesis from different types of questionnaires, it 




● Appendix 1: Example of first red questionnaire. Serie 11 (Paper I and Paper II); 
● Appendix 2: Example second green questionnaire. Series 28-29 (Paper I and Paper II);  
● Appendix 3: Example for pamphlets on OC and hormone replacement therapy. (Paper I, 
Paper II and Paper III); 
● Appendix 4: Example third yellow questionnaire. Serie 39 (Paper I and Paper II); 
● Appendix 5: Letter of invitation and information to the NOWAC study; 
● Appendix 6: Example of English version of blood questionnaires; 
Paper I and Paper II are restricted to postmenopausal women due to limited number of 
premenopausal women who had information required for subgroup analyses available. At the same 
time, in paper III we included both pre- and postmenopausal women. This approach was chosen to 
keep as much cases as it possible due to complexity of the study design. The other inclusion criteria 
along with exclusion criteria are otherwise specifically described in the next sections devoted to 
each paper. 
 
3.3 Study sample for Paper I 
For different subgroup analysis in Paper I we used the data from NOWAC questionnaires of 
different series and years (Figure 17), but initial sample size was based on women who filled in the 
baseline questionnaires 1991-1997 and 2003-2007 (all-together 129 854 women). 
We then selected those who was postmenopausal from the start-point of inclusion to the study or 
became postmenopausal by the end of the follow-up for this paper, which was set to 31st of 
December 2010. After all exclusions highlighted in Paper I, we ended up with 97 926 









3.4 Study sample for Paper II 
With the only exception on age at menopause, the information about other variables used in analysis 
for paper II was obtained from the baseline questionnaires (first “red questionnaires”), which were 
received by women in the period 1996-2006 (Figure 18). Women’s age at entrance to the current 
study varied from 27 to 65 years with the largest group among those who were between 42 and 58 
years old (87%). For those women, who became postmenopausal later during the follow-up (from 
the start of the current study until 31 December 2014, we used updated information on 
postmenopausal status from the follow-up questionnaires (second “green questionnaires”). After all 
exclusions, which are in details described in corresponding paper II, the final study cohort included 
117 589 postmenopausal women, of which 720 women developed incident EC. 
 
3.5 Study sample for Paper III 
Paper III is nested case-control study based on information obtained from 8-pages questionnaires 
and blood samples collected in 2002-2005 (Figure 18). The main concept of this paper represents a 
systems epidemiology approach by testing the epidemiological hypotheses obtained from a large-
scale data on a gene expression level data within the same cohort. We therefore chosen the 
factors/variables, which were evaluated in paper I/paper II and among them selected those, that had 
strongest effect on EC risk in the whole NOWAC cohort. The main steps of selecting the NOWAC 
participants and exclusions based on quality control procedures are in details described in 
corresponding paper. 
After all exclusions based on quality control described in details in paper III, the final 
dataset available for analysis consisted of 158 individuals (79 case-control pairs) with 47 248 




Figure 18.  Data used in paper II and III. Based on enrollment to Norwegian Woman and Cancer Study. 
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3.6 Central variables 
Coffee variable  
Information on coffee consumption was derived from NOWAC questionnaires (example in 
Appendix 1), where the women were asked to report how often they consumed the coffee during the 
preceding year by ticking suggested fixed frequencies. Of note, this information was very 
differently presented in various series of first, second and third questionnaires. For example, 
questionnaires from 1991 to 1995 in general had a very limited number of dietary questions 
compared to 1996 and onwards. In addition, the formulation of coffee questions differed along the 
whole way of recruitment and follow-up. As a result, one group of women got the questions just on 
total consumption while another group answered just on their preferences in different brewing 
types. The distribution of number of participants and cases that had information on a certain type of 
coffee is illustrated in Appendix 7. 
Formulation of “number of cups categories” were also differently presented. In order to 
increase the statistical power and sample size, we have pooled the data together and got a common 
version of frequencies for both the total coffee version and the brewing method version of the 
questionnaires (Appendix 8).  
 
LNYM variable  
Lifetime number of years of menstruation (LNYM) is a central variable of paper II and one of the 
investigated risk factors in paper III. This is a composite variable, which was calculated in a 
following way: 
LNYM = age at menopause minus age at menarche minus cumulative duration of full term 
pregnancies (calculated as the number of full-term pregnancies, including live and stillbirths, times 
0.75 years) minus duration of breastfeeding (calculated as the cumulative number of months of 
breastfeeding in all pregnancies) and minus duration of OC use, minus 12 weeks for each 
incomplete pregnancy (for those women who had this information available). All the mentioned 
variables were added on a continuous scale in years.  LNYM was further classified into 5 
categories: <25, 25-29, 30-25 34, 35-39, ≥40. Additional analysis related to including incomplete 







Parity was calculated as categorical variable for showing distribution in all three papers. As a 
continuous variable, parity was used for adjustment in multivariate analysis in paper I and as a part 
of LNYM in paper II.  In paper III, parity is a central variable that was also calculated on a 
continuous scale, showing the changes in gene expression within having each additional child.  
 
Body mass index (BMI) 
BMI was calculated as weight divided by height squared (kg/m2). For all three papers we used 
information on height and weight that were measured at baseline (first time the participants filled 
the questionnaires containing these questions). For paper I and paper II, BMI was categorized as 
<20, 20-24.9, 25-29.9, and  ≥30 to show the detailed distribution. In the subgroup analysis of these 
papers BMI was classified into 2 categories: <25 and ≥25. For paper III, BMI was calculated as a 
continuous variable.  
 
Menopausal status/age at menopause 
Both for paper I and paper II menopausal status was derived from the questions on menstrual 
regularity. Women were classified as premenopausal if they answered that they still had regular 
menstruation. If women reported that their menstruation had stopped at the time of enrollment or 
during the follow-up they were classified as postmenopausal. However, we have differently treated 
the missing information on this variable in paper I and paper II. In paper I, in case of uncertain 
information (irregular menstruations, MHT use or otherwise insufficient information) we set 53 
years old as a cut-off for age at menopause as it was previously used in earlier NOWAC reports 
based on the definition used in The Million Women Study (192). In paper II, missing information 
on age at menopause was treated according to smoking status as the recent publications showed that 
women who smoke have earlier menopause (193).  
 In paper III, due to a limited sample size we have included both pre- and postmenopausal 
women, but have used “age at menopause” as a continuous variable, showing how gene expression 
changes with increase of age at menopause.  
 
OC use 





Smoking status in paper I and II was coded as never, former, current or missing. Women who 
reported either being current or former smokers were also categorized as “ever smokers”. Duration 
of smoking and number of cigarettes were not considered in the papers included in this thesis.  
 
Data from Cancer registry of Norway 
The Cancer Registry of Norway is one of the oldest national cancer registries in the world 
(established in 1951). It is obligatory for all medical practitioners in Norway to notify about the new 
cancer cases and for pathology departments to send the copies of their reports to the Cancer 
Registry. By 2001-2005 the completeness of recording uterine cancer cases was high (99%) (194).  
 Topography codes were converted first to ICD 7th version in 1970 and then to ICD-10 in 
1993. At the present time, The Cancer Registry of Norway provides information for both ICD-7 and 
ICD-10. For all three papers, we have used ICD Revision 7 and 10 with corresponding code 172 for 
corpus uteri in ICD-7 and analogue code C54 from ICD-10. Using different ICD-coding did not 
affect the main findings of our papers. 
 
3.7 Statistical methods 
The main focus of this thesis is not connected to statistical analysis, therefore only brief description 
of the used methods will be mentioned here. Otherwise, more detailed information on statistical 
steps could be found in respective papers.  
Statistical analysis was performed using SAS version 9.2 and STATA version 14.0 for paper 
I and paper II respectively. Cox proportional hazard regression models (195) were used to examine 
the association between the relevant exposure variables and postmenopausal EC risk. Multivariate 
analysis in both papers was carried out to control for the potential confounding effect of other 
variables (for details see corresponding papers). The analyses of Schoenfeld residuals were used to 
test the proportional hazard assumptions and there was no evidence of deviation from 
proportionality. We also used Wald test to assess the heterogeneity in effects between different 
brewing methods (paper I) and to check for any non-linear relationship between LNYM-variable 
and postmenopausal EC risk. In paper II we have also used Royston-Parmar flexible parametric 
proportional hazard models (196) to estimate the baseline HRs according to different LNYM 




Gene expression analysis for paper III was performed at the Norwegian Computing Center. 
The analysis was done by using R with Bioconductor packages. First, potential confounders were 
evaluated by comparing cases and controls using independent sample t-test, Mann Whitney U-tests 
and Chi square tests. Then, using Limma packages (198) analysis with gene-wise linear models was 
conducted in order to evaluate the difference in single gene expression between cases and controls. 
The same method was used to identify the differentially expressed gene sets and to evaluate 
whether these genes and gene sets were influenced by one of the variables (parity, LNYM, coffee 
consumption, BMI or age at menopause). Description of steps in statistical analyses with equations 








High coffee consumption and different brewing methods in relation to postmenopausal 
endometrial cancer risk in the Norwegian women and cancer study: a population-based 
prospective study. 
 
For the present analysis we included 97 926 postmenopausal Norwegian women from the 
population-based prospective Norwegian Women and Cancer (NOWAC) Study. Among them, 462 
developed incident EC during an average of 10.9 years of follow-up. After multivariate adjustment, 
we found a significant risk reduction among participants who drank ≥8 cups/day of coffee with a 
hazard ratio of 0.52 (95% confidence interval, CI 0.34-0.79). We did not observe a significant dose-
response relationship. We also did not observe significant heterogeneity in risk when comparing 
filtered and boiled coffee brewing methods. A reduction in EC risk was observed in subgroup 
analyses among participants who drank ≥8 cups/day and had a BMI ≥25 kg/m2, and in current 
smokers. The results of this paper suggest that in Norway, in population with historically high 
coffee consumption rates, EC risk decreases in women consuming ≥8 cups/day, independent of 
brewing method. According to our results the protective effect of coffee consumption is more 




Lifetime number of years of menstruation as a risk index for postmenopausal endometrial 
cancer in the Norwegian Women and Cancer Study. 
 
Lifetime number of years of menstruation (LNYM) is a measure the effect of all reproductive 
factors combined, reflecting the cumulative endogenous estrogenic exposure during lifetime. Based 
on the data from a prospective population-based cohort study of 117 589 postmenopausal women, 
including 720 EC cases, we studied association between the number of years of menstruation and 
EC risk. Lifetime number of years of menstruation (LNYM) were computed taking into account age 
at menarche, age at menopause, cumulative duration of full-term and incomplete pregnancies, 
breastfeeding duration and duration of OC use. Using Cox proportional-hazards model, we found a 
statistically significant linear relationship between LNYM and EC, with a 9.1 % increase in risk per 
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year (p for trend < 0.001). The risk of EC increased gradually along with increasing duration of 
menstrual span. Using the group ≥ 40 years of menstruation as a reference, the hazard ratio for 
group <25, 25-29, 30-34, 35-39 were 0.17 (95% CI 0.22-0.27), 0.25(95% CI 0.17-0.36), 0.43 (95% 
CI 0.32-0.58) and 0.68 (95% CI 0.51-0.92), respectively. The linear relationship remained 
significant after stratification for BMI, adjustment for diabetes, hormone therapy, and incomplete 
pregnancies. We found similar associations among all strata of BMI and among non-users of OC. In 
addition, due to a strong dose-dependent association between LNYM and EC risk we were able to 
calculate PAF in 5 years-interval. PAF calculations showed that if women with LNYM ≥35 
decreased LNYM to less than 35 years, 48% of EC could be avoided. The proportion of avoided 
cases increase to 64% and 67%, if the cut-off for LNYM category changed to 20 and 25 years 
respectively. 
In line with previous reports, our study support that increasing lifetime number of years of 





Gene expression profiling of peripheral blood according to endometrial cancer risk factors: 
systems epidemiology approach in NOWAC Postgenome Cohort Study. 
 
Increasing worldwide incidence of EC, the most common gynecologic cancer in the world, requires 
extensive search for novel preventive tools and early intervention approaches. Several factors, 
including parity status, breastfeeding duration, use of OC, coffee consumption, BMI, use of 
hormone replacement therapy, and lifetime number of years of menstruation have previously been 
reported to modify EC risk. However, establishment of reliable predictive models is impossible 
without knowledge on genetic changes prior to diagnosis. In this work, we aimed to establish if 
known EC risk factors influence peripheral blood gene expression in a prospective design. First, we 
selected variables that were shown to have an impact on EC risk in the whole Norwegian Women 
and Cancer (NOWAC) cohort (165 000 women). Then, we tested the association between these 
variables and changes in gene expression profiles in blood in a nested case-control study (79 case-
control pairs) of women from the NOWAC postgenome cohort. Lastly, we undertook a gene set 
enrichment analysis (GSEA). When we looked at overall gene expression, we found no difference 
between EC cases and controls. Introduction of parity status into the statistical model, revealed 
changes in expression of 1379 genes (false discovery rate (FDR) 20%) in controls, while we did not 
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observe any expression changes in cases. 27 genes (FDR 20%) were associated with BMI increase 
in controls, whereas there was no association between changes in BMI and gene expression in 
women with EC. In GSEA, the major part of significantly enriched gene sets (2407, FDR 20%) 
were attributed to parity increase among cancer-free women. We found that increased number of 
parities has a major impact on changes in peripheral blood gene expression in women diagnosed 
with EC later in life. The descriptive study design does not allow us to provide accurate explanation 
of our findings in biologic terms but this work brings solid background for further research on the 




5. GENERAL DISCUSSION 
This PhD project is one of the examples of the developing field of systems epidemiology, where 
unique combination of both lifestyle exposure and information on functional genomics will 
hopefully give more understanding in the processes involved in endometrial carcinogenesis. Such 
multidisciplinary projects, however, also have many aspects for quality control and a lot of 
challenges when it comes to methodology. Therefore, the first part of the discussion is devoted to 
methodological issues and the second part describes the interpretation of the obtained results in the 
light of existing literature. 
 
5.1 Methodological challenges 
In the world of competitive research inaccurate reporting of data is not a seldom event. This 
hampers the generalizability and correct interpretation of results both for the whole research 
community and for future patients especially when it comes to diagnostics or treatment of such 
diseases like cancer. Thus, quality control of data should be an integral and essential part in research 
at various stages and first of all before data gathering starts. 
 
5.1.1 General issues related to NOWAC study 
Study design 
The present project will focus on a study with observed data based on prospective design, although 
to date many researchers investigating cancer have also used cross-sectional and other types of 
case-control studies as a model. It is known that cross-sectional design can provide information 
about possible association between exposure and outcome (199), but since the information is 
obtained at a given point of time it is difficult to make any conclusions about the causality of this 
association. In this context, using a prospective design like in NOWAC Study is more safe and 
reliable as the exposure is measured before the outcome and therefore the time-effect relationship is 
known (200). Another advantage of using a prospective design is an excess to follow-up, which is 
in case of NOWAC is complete due to unique opportunity to use the linkage to national registries 
such as mortality registry, migration registry and cancer registry (201).  
When it comes to integrated systems epidemiology analysis, the initially correct planning of 
the study design is particular essential. In order to succeed in catching of any significant 
associations between exposures and related changes in gene expression, the studied cohort should 
be first of all, large enough to reach the sufficient calculation power. NOWAC study has a large 
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sample size and random sampling, which reduce sampling errors and therefore increases the 
precision of estimates. Prospective design and involving of many participants gives enough 
statistical power to detect small differences in smaller subgroups like NOWAC Postgenome Cohort 
using a nested case-control design. Moreover, using a representative smaller subcohort is more 
practical in terms of high costs of all kind of functional genomic analyses. Secondly, NOWAC 
Postgenome Cohort is constructed in a such way that in a matched case-control design all the cases 
ad controls were kept together through the all steps of laboratory work. This approach aims to avoid 
batch effects and systematic bias. Finally, this unique design allows testing the hypothesis in 
functional genomic obtained earlier from the same cohort like it was demonstrated in paper III. This 
approach minimizes many types of bias and measurements errors, which are known to occur if for 
example if the testing hypothesis is derived from the study from another country, which could differ 
in sampling procedures and simply different patterns of lifestyle characteristics. 
 
Validity 
Validity represents the level of confidence that we can put to the studied cause-effect relationship 
and investigates whether the obtained findings represent the real situation (202). Internal validity 
evaluates whether the results are correct for the studied group of participants, e.g. if the current 
study gives unbiased results (203, 204). Implying this definition to the current thesis, internal 
validity assesses if the observed difference between the studied groups related to our dependent 
variable (EC risk) is attributed to the studied exposure (coffee consumption, LNYM, parity, age at 
menopause, OC use or BMI). External validity (representativeness or generalizability) shows if the 
chosen population in a given study (in our case, NOWAC Study) differs from the general 
population, and whether participants differ from non-participants. This type of validity is generally 
good secured in NOWAC as this study has a random selection of participants though the Central 
Population Registry. However, as participants anyway “select themselves” and decide to participate 
or not, the possibility of invalidity of study arise and thus, methodological studies could be of great 
help. Such evaluation of validity has been done within NOWAC as well. Evaluation of data from 
Cancer registry of Norway showed that cumulative incidence rates (CIR) in NOWAC for all cancer 
sites included EC in women of the same age were almost identical with the corresponding CIR for 
the entire population (205). External validity is also particular important in terms of possibility of 
estimating the public health effects of a given association by calculating absolute or attributable 
risks. The analysis of validity study from NOWAC did not reveal major source of bias that could 
make calculations of population attributable risks invalid.  
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 However, still the number of different types of errors can be rather overwhelming due to so 
many sources of possible bias that are identified in modern research, and in this part of discussion I 
will mainly focus on the 2 main groups of possible bias: selection bias and information bias. The 
role of confounding will be later mentioned in the discussion of the main results.  
 
Selection bias 
Selection bias results from skewed selection to participation or follow-up. In spite of rather high 
participation rate in NOWAC Study (57%), there is still a chance of getting selection bias if the 
non-participants had a systematically different risk profile than the participants. Of course, we 
cannot be certain whether the participants have higher or lower frequencies of risk factors than non-
participants. And as we do not have any relevant information about the non-participants, it is 
difficult to assess the direction of the possible selection bias.  
 Validity evaluations from NOWAC showed that the highest response rate was among the 
women from Northern Norway, that response rate was higher for short questionnaires and decreased 
with the increasing of age of those who received questionnaires (189). In case of EC, it could lead 
however to selection bias as EC is strongly associated with age. Thus, if among non-participants 
there was a high rate of elderly women, we could have underestimated the effect of age on EC risk. 
In addition, if for example obese women or ex-active users of MHT are in particular among the 
elderly women, the impact of these variables may be also underestimated.  Using the data from 
Norwegian fertility registry and registry of education it was shown that women who agreed to 
participate had higher age at first birth and more than 12 years of education in comparison to source 
population. However, for example, proportion of women with three or more children was 
approximately the same among responders and non-responders. Validity studies within NOWAC in 
general showed no significant differences while comparing the distribution of exposure variables in 
samples with response rates from 55 to 70% (206). Another NOWAC study (189) investigated 
possible selection bias comparing women responding to the NOWAC follow-up questionnaire and 
women responding to the NOWAC baseline questionnaire in relation to the information given at 
enrolment. Almost no differences were found, except the fact that those women who completed the 
follow-up questionnaires were slightly younger and better educated. In accordance to this, a certain 
percent of selection bias must be expected among the participants of the Postgenome cohort as they 
participated and filled inn questionnaires several times due to a specific recruitment process to this 
sub-cohort. However, expect educational level and MHT use, there were no major differences 
among NOWAC participants who donated blood and responded only once compared to those, who 




Information or measurement bias occurs when the study subjects or personnel/instruments give 
systematically inaccurate measurements or there is a systematical difference in the way data is 
obtained (208). This may affect both independent and dependent variables. Recall bias (differential 
bias) refers to disease/outcome status and can arise when for example, cases and non-cases 
remember the exposure information differently. However, in case of NOWAC study, recall bias will 
be generally prevented due to prospective design, meaning the assessment of exposure information 
before the occurrence of cancer. Non-differential misclassification on contrary results when 
misclassification of either exposure or outcome is not linked to exposure or outcome status. And, 
since NOWAC study represents a big cohort and all participants are equally measured using the 
same questionnaire or blood collection kits the possible misclassification bias will be mostly non-
differential. 
 
The role of confounding 
Confounding occurs when there is the confusion of two supposedly causal variables, and the effect 
we observe in a studied association by one variable is actually due to the effect of another variable 
(209). It is well-known, that most proposed risk factors for EC interact with each other and 
therefore can alter the studied association. For example, obesity in many cases leads to chronic 
anovulation and infertility, as a result we could observe many nulliparous women with high BMI. 
However, nulliparity by itself is a risk factor for EC, and lack of controlling of this factor can also 
lead to an overestimation of the impact of obesity. On the other hand, it is also well known, that 
BMI increases with increasing parity, which on contrary is linked to inverse association with EC. 
This example shows, how complicated is relationship between these hormone-associated risk 
factors in EC development. In order to avoid the effect of potential confounding, in Paper I and 
Paper II depending on model, we have used multivariate analysis adjusted for age, parity, smoking, 
BMI, MHT use and OC use. However, it is always important to keep in mind, that obtained results 
may also be influenced other unmeasured variables, not yet known to be related to EC.  
 
5.1.2 Validity of variables used in the present thesis 
Age at menopause 
Menopausal status is one of the central variables in all three papers. Due to its nature of being a 
prolonged biological process, start of menopause could be difficult to identify and this could 
logically lead to inconsistent recall of a precise menopausal age. This could also explain the higher 
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difference between self-reported age at menopause and accurate age in natural menopause 
compared to menopause caused by other reasons like operation or hormone intake. However, in the 
majority of validity studies, self-reported age at menopause is considered to have a good reliability 
(210-212). 
Self-reported age at menopause was also validated by NOWAC in a study provided by 
Waaseth et al (213). In this study the measurement of plasma levels of E2 (cut-off for 
postmenopausal women < 0.2) and FSH (cut-off for postmenopausal women> 0.26) were used to 
validate menopausal status/classification used in both blood (two-pages) and standard 
questionnaires (eight-pages) (213). The study revealed, that NOWAC data provide a valid 
information on menopausal status, showing 92% sensitivity (95% CI 89–96%) and 73% specificity 
(95% CI 64–82%) for this variable in blood questionnaire, and 88% sensitivity (95% CI 84–92%) 
and 87% specificity (95% CI 80–94%) in standard eight-pages questionnaire respectively. 
However, such validation of menopausal status using plasma concentration of E2 and FSH 
is not suitable for all analogue studies, as it requires the presence of blood samples for all women. 
Moreover, there is still no independent established serum biomarker for accurate identifying of 
menopause, so for many studies self-reported retrospective information is still the only one option 
(214). 
 
Age at menarche 
Age at menarche was included in paper II as the start point of calculating LNYM. As it was 
obtained as a retrospectively self-reported information with a long-term perspective back in time, 
recall bias could be particularly present here. Moreover, along with information on age at menarche, 
other factors like weight, height, level of physical activity in adulthood and medical records on 
presence of anorexia nervosa or any other hormone-associated diseases should be also taken into 
account as they are shown to modify the start of menstrual function (215). It is known, that on 
average the first menstrual bleeding occurs between 10 and 15 years (216), but according to some 
reports (217) age at menarche decreased dramatically since 19th century worldwide, including 
Northern Europe. However, studies obtained from Norway showed that menarcheal age was close 
to stable and between 13.1-13.3 years since 1950’s (218), which in accordance to the mean age at 
menarche in all three papers in this thesis. Moreover, studies that validated self-reported age at 
menarche revealed relatively high correlation between self-reported information and correct data 
obtained in adulthood with quite Pearson’s correlation ranged from 0.52 to 0.83 (219, 220). In 
recently published analogue study based on Tromsø Study Cohort (216), Pearson’s correlation was 
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0,84 and was not attenuated by increasing age of women when they had to recall this information. 
All in all, these studies give a solid background to conclude that self-reported age at menarche is 
relatively accurate to be used in epidemiological studies.  
 
Parity and pregnancy-related variables  
Parity was among the variables that received the highest validation in a validity study provided by 
NOWAC (205). Moreover, parity has been stable since the end of the 1970’s, although there was a 
decreasing in parity from 1970 (Figure 19).  
 
Figure 19. Average number of parities in Norwegian population. Raw data obtained from Statistics Norway. 
 
Breastfeeding rates varied a lot over the years. In 1960s only 20% of Norwegian women 
breastfed until the baby was 3 months old. Revolutionary introduction of “Breastfeeding-help” in 
Norway in 1968 led to raise of breastfeeding rates and already from 1980’s the introduction of new 
public breastfeeding policy at obstetrics departments all over the country and extending of 
maternity leaves in Norway led to increased public focus on breastfeeding (221). Women that were 
included in paper II had their fertile years (with potential for breastfeeding) during these 70s-90s 
when there was an increased attention to changings in breastfeeding policy, thus it could give us 










Validation of questions related to incomplete pregnancies and abortions is always more 
challenging due ethical specificity of these issues. In general, response-surveys on abortion show 
that response rate differs a lot depending on several factors. Thus, in some surveys, unmarried 
women compared to married were less likely to report abortions, women with fewer children were 
also less likely to report abortions compared to those who gave birth to more than 3 children (222). 
Moreover, the response rate could be affected by the way the question was asked. For example, in 
the first versions of NOWAC questionnaires question on abortion were divided into spontaneous 
and induced. This subdividing was replaced by general questions on all abortions in general because 
of social stigmatization of having induced abortion. In Norway, the women’s right for induced 
abortion was legalized in 1978. Until 2005 Statistical central register was responsible for 
registration all induced abortions in Norway. In 2005-2006 National Health Institute of Norway 
took over this responsibility and, and finally in 2006 Abort Registry was developed. Thus, there is 
available statistics giving the overview of the number of induced abortions since 1978. Moreover, it 
has been reported that he number of induced abortions in Norway was stable over the years in all 
fertile groups and in general the prevalence is not high compared to other countries (223). 
  
Oral contraceptive and MHT use 
Since OC and MHT use are not constant characteristics, misclassification and misreporting for these 
variables can arise. For both OC and MHT users, NOWAC performed validation by reproducibility 
tests.  
Data from Drug Consumption in Norway based on Defined Daily Doses (DDDs/day) 
indicate that the total use of oral and transdermal hormonal contraceptives increased from 20 000 in 
1967 to 200 000 in 2000 and 270 000 in 2016 (Figure 20) (224). In Norway, combined OC’s had a 
dominant frequency of use in the period 1967 with the first peak of use in 1981 and 5-years 
following fall, stable sale rates in 1991-1995 along paralleled with sequential OC’s (Figure 20 
upper panel) (77). An interesting trend is then observed in 2 periods. The first one, from 1995 to 
2000 when combined OC’s undergone of dramatic fall of sales but sequential OC’s on contrary, had 
a parallel rise of sales. The second 5 years (2000-2005) the opposite scenario has been observed. 
Finally, since 2006 combine OC’s got a rising and dominant frequency of use up to date (Figure 20 





Figure 20. Sales of oral and transdermal hormonal contraceptives in Norway between 1967 and 1997 (upper panel) 
and between 1990 and 2016 (lower panel). 
Adapted with permission, copyright 2006, 2017 by Norwegian Institute of Public Health 
In order to receive more precise information about OC use, in 1991 all women invited to 
participate in NOWAC Study also received a booklet with photographs of 33 of the 36 known OC 
brand sold in Norway. Three months after returning the first questionnaire, women received a 
second identical questionnaire, which were answered by 61.1% of earlier responders. Information 
on the new OC types was updated in each new version of questionnaires. In order to acquire the 
extent and level for agreement between these two responses in accordance to OC ever use, current 
use, use before the first full time pregnancy kappa was used, showing satisfactory agreement for all 
the categories mentioned above (k=0.97, k=0.86, k=0.87 respectively). As one of the limitations for 
65 
 
our LNYM study (paper II) one can mention absence of updated information about any changes in 
exposure status in OC during as this information was obtained only from baseline questionnaire.  
When it comes to MHT use, so together with validation of menopausal status, study of Marit 
et al (207, 213) evaluated the validation of current users, showing 100% specificity. Former users of 
hormonal preparation are always less reliable in their reporting compared to current users. As for 
OC use, to recall former MHT use in NOWAC, women received a prospect with photos for all 
known brands of menopausal hormonal preparations that were available on Norwegian 
pharmacological market since 1953. However, we could expect some underreporting because of 
general awareness and controversial information about potential harmful or beneficial effects of 
MHT during the periods, when the participants of our studies answered these questions. In Norway 
the first MHT preparation based on ethinylestradiol and the first patch (Estraderm) containing  
estradiol were introduced in 1953 and 1989 respectively (225). Preparations contained progestins 
were first available in Norway since 1960. Later, during 1990s other MHT preparations as tibolone, 
vaginal ring and other progestins joined the Norwegian drug market. Later, norethisterone and 
levonorgestrel became the most preferable progestins that have been used in Norway (225).  
Generally, Norwegian women were somewhat restrictive in use of MHT comprising less than 6% of 
users among postmenopausal women in the late 1980s (226). Further then, the pattern of use has 
changed in the 90s the use of MHT preparations increased and accounted for 35% of 
postmenopausal users. In this period, the users of estrogen-progestagen preparations comprised 
70% of all MHT users in Norway. In accordance to analogue reports from other countries, in 
Norway this type of MHT has not been shown to increase EC risk in contrast to estrogen-only 
regimens which gave RR 3.2 (CI 95% 1.2-8.0) (192). Unfortunately, we do not know for sure, if 
there is or not misclassification in category “former MHT users”. For some of the analogue studies 
in Norway, linkage to the Norwegian Prescription Database, would have been one of the best 
alternative ways to validate the information on former MHT use. However, it was founded just in 
2004, thus this type of validation is not suitable for our study as information on MHT use was 
collected long before this date.  
 
LNYM as a chosen version of total estrogen exposure measurement. Challenges with comparing 
with analogue studies.  
As it was illustrated in Introduction section (Table 4), there is a big heterogeneity between analogue 
reports and up to date there is no standard or common method to calculate the lifetime number of 
menstruations or number of cycles. Indeed, the methodological study provided by Yang et al (118) 
that investigated the correlation between different algorithms for computing lifetime number of 
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cycles, showed an elevated EC risk in the highest quartile of cycles (408.0-602.3, corresponding to 
34-50.2 years), but this was statistically significant (odds ratio 1.95, 95% CI: 1.11,3.44) only in one 
of 5 tested algorithms. Moreover, it has been shown, that the choice of mathematical algorithm used 
in the calculation of a core composite variable might by itself independently effect the studied 
association (118).  
In our study, we have chosen to use years of menstruations instead of number of cycles due 
to fewer number of uncertain factors that is difficult to validate compared to calculating of number 
of cycles, which is considered to be more imprecise due to more factors that should be taken into 
account in calculation but difficult to measure such as for example, individual validity of cycle 
length, and regularity of the cycles. However, it was reported by several studies that cycle length 
and regularity were unrelated to EC risk (107). Moreover, when it comes to using cycles as an 
indicator for cumulative estrogen exposure and EC risk, it is essential to distinguish, whether the 
cycle was ovulatory or not. Further, it is shown, by some studies that ovulatory cycles and LNYM 
might be two different independent risk factors (227). Therefore, as a baseline for our study we used 
the formula for calculating LNYM from EPIC study (98) as the authors used quite a standard 
approach with using minimum of required components, such as age at menarche, age at menopause, 
number of pregnancies, duration of breastfeeding and OC use. However, EPIC has a limitation of 
using information from different centers, where questions on required variables could be formulated 
and collected in a different way. There is a need for such “LNYM” studies in general and within 
each of participating cohorts in EPIC in order to have a better comparison. In this context, one of 
the strengths of our study is that we provide the results for comparison with future studies, showing 
both  a “standard” approach of calculating LNYM (age at menopause, age at menarche, number of 
full-term pregnancies, duration of breastfeeding and OC use) (see different models in paper 3, Table 
3) and in addition, other alternatives of calculating the LNYM for those studies, that like ours, had 
for example supplementary data on different types of incomplete pregnancies. 
 
BMI 
Challenges in validation of self-reported information on BMI is a well-described problem for 
epidemiological surveys using questionnaire data. Validation of this information was also 
performed in NOWAC (228). This study showed that although there was in general a substational 
agreement between self-reported and values measured by medical staff, there was an underreporting 
of weight in overweight and especially in obese women. Such underreporting of BMI could have 
effect the results of subgroup analysis for BMI categories (indeed, we had few women in “obese 
category”), however, in case of paper II and paper III, this variable was included as a continuous 
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variable and did not affect the main results. In paper I, we have reported that protective effect 
among those who consumed 8 or more cups of coffee was stronger in obese women. These findings 
are indeed in line with the results from recently published meta-analyses, showing more pronounced 
protective effect of coffee consumption in overweight and obese women (178). 
As other acquired life-style factors, body weight can also change during follow-up. Previous 
reports (229)  pointed the importance of weight change over time. Most of them showed that an 
increased EC risk may be attributed to increase in weight at age 18-25, even after adjusting for 
current BMI. Interestingly, replicating of these results in non-Western populations also showed a 
positive association between obesity at age 20 and EC development (230). Body fatness in 
childhood is showed to be less significant, however, still remains important as it correlates with 
adult obesity, and thus, many adverse health outcomes, including cancer (231). In one of the 
NOWAC Studies, it has been recently shown (unpublished data by Rylander et al, article under 
review) that both moderate weight gain (5-10 kg) and high weight gain were associated with 
increased risk of EC, independently of high BMI at baseline. However, the association was weaker 
for weight gain than for high BMI itself (personal communication with Rylander). 
  It is shown, that in contrast to BMI, measurement assessing the extent of central versus 
peripheral obesity is better predictor for other hormone-dependent cancers like for example BC 
(232). Thus, measurement is based on a ratio of waist to hip circumference, where value 0.8 and 
higher is associated with central adiposity and following metabolic phenotype, independent of 
weight and thus, BMI (233). In contrast to other cancer types, studies investigating relationship 
between waist/hip ratio and risk of EC have been sparse and inconsistent. A population based case-
control study from Shanghai showed a particular role of upper-body obesity, which was associated 
with increased EC in spite of low BMI (234). A meta-analysis of prospective observational studies 
reported a non-significant increase in EC risk within each 0.1 unit increase in waist and hip 
circumference. However, when waist and hip were taken into the risk assessment separately, they 
had also shown independent risk increase with RR 2.16 and 1.30 per 10 cm increase in waist and 
hip circumference respectively (229). The importance of waist to hip measurement becoming more 
and more relevant taking into account that central obesity is strongly associated with other EC risk 
factors, such as hyperinsulinemia and diabetes type II (235). Finally, as an additional validation for 
BMI, measurements of levels of adiponectin, which is secreted by adipose tissue, could be used as a 
serum biomarker for obesity. The levels of adiponectin are inversely correlated with BMI (236) and 
EC risk, showing that each 5 μg/mL increase of adiponectin level reduces the risk of EC by 18%, 





Although smoking is not the central exposure in all three papers, it is indeed an important 
modulator of hormonal metabolism in women especially in postmenopausal period, and therefore, is 
important confounder that should be included in risk assessment models. Smoking information in 
NOWAC was obtained from self-reported questionnaires at baseline, and by present time no 
validity studies have been performed. Therefore, several methodological challenges in interpretation 
of our results from subanalysis in paper I and paper II can occur. First of all, we cannot exclude the 
possibility of selection bias due to “healthy volunteers effect” (238). Further, in our studies we have 
focused just on smoking status as former, current, never without including details like age at 
smoking initiation, smoking duration, number of cigarettes smoked per day and pack-years. In 
addition, no data was available on passive and occasional smoking, so these categories are included 
in the group “never smokers”. Then, we do not used information about any changings in smoking 
behavior during the follow-up. Results from Million Women Study showed that in their study of 
those who were current smokers at baseline, 20% and 44 % quit to smoke after 3 years and 8 years 
respectively (239). However, in case of postmenopausal EC, which is our focus for paper I and 
paper II, it has been shown that both current smokers at baseline and those who quit ≥5 years before 
baseline had significantly reduced risk of EC compared to never smokers (134). 
 
Coffee consumption 
All the studies investigation the components of diet as a potential exposure are always at certain risk 
of rising various types of bias, and studies focusing on coffee consumption are not the exceptions. 
Among the problems that arise, might be first of all inaccurate measuring of caffeine consumption 
along with other bioactive compounds from other sources in diet, like tea, cola, chocolate and 
energy drinks as this type of information was not available from NOWAC questionnaires. Further, 
it is also challenging to investigate real changes in the amount of coffee consumed during the 
follow-up or differences in the cup size and coffee strength. Coffee habits vary much between the 
individuals - some prefer small amounts of strong coffee like espresso, others drink large amounts 
of instant coffee. So even though these coffee types contain different amount of caffeine, sometimes 
it could be equalized by the size of the cup. Hence, in human studies it is difficult to get the final 
conclusion regarding the effect of one or another type of coffee. Although some other studies 
showed the satisfactory reproducibility and validity of information on coffee (240) still various bias 
could arise with coffee assessment extracted from self-reporting food-frequency questionnaires.  
In order to update the exposure information (e.g. dietary intake) NOWAC FFQs have been 
investigated in several validity studies. To increase reproducibility and validity these questionnaires 
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were tested in terms of biomarkers and 24-hour dietary recalls and have been shown to be in the 
same range as similar studies have (241).  Precisely to coffee consumption, the validity of estimates 
of this beverage was fairly good as well. 
 
5.1.3 Technical considerations in gene expression analysis (Paper III) 
Validation of the methods and findings demonstrated in paper III was not the key focus for this 
study due to the exploratory and “testing” concept. However, many of the challenges related to 
validation and interpretation of results are generally common for many analogous gene expression 
studies. Implementation of microarray technique into the large-scale epidemiological studies along 
with limited standardization of methods used on different steps of analyses, introduced a variety of 
factors that we should be aware of. Both pre-analytical issues and analytical errors as well as within 
and between subject variations might significantly influence results. 
All pre-analytical steps of microarray including mRNA isolation, cDNA synthesis, labeling, 
hybridization, washing, and scanning could produce random or systematic errors. In addition, 
contamination of samples and technically inaccurate work performed by the lab personnel can take 
place. Finally, blood samples are always prone to RNA degradation due to the presence of RNase. 
A study by Dumeaux et al (242) revealed that 46,5% of the overall variation in gene expression is 
attributed to three technical variables in the pre-analytical step: transportation time (time between 
blood sample collection and freezing of the sample) and RNA extraction time (time between blood 
sampling and RNA isolation). In paper III, we have checked the difference between the time of 
blood sampling and RNA extraction, which showed that the difference between cases and controls 
regarding time between these two events does not exceed 10 days. All blood samples used for paper 
III, were collected by the PAXgene blood RNA collecting system, which was shown to work well 
in terms of effects of pre-storage handling, storage over time and RNA isolation output (243). 
Validation studies of data obtained in microarray demonstrate, in general, good agreement with the 
results obtained by more sensitive techniques including quantitative reverse transcription 
polymerase chain reaction (qRT-PCR) and next generation sequencing (NGS) (244-247). Although, 
it has been demonstrated that genes with largest fluctuations in expression levels (both positive and 
negative) have better concordance than genes exhibiting modest changes (248). Thus, in paper III, 
we assessed trends in differential expression and, therefore, maximized the significance of obtained 
results as it has been shown in other studies that interpretation of microarray data should be rather 
based on relative expression levels than on absolute numbers (248).  
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The role of microarray data preprocessing has been emphasized by various sources (249, 250). 
During the initial steps of Paper III preparation, we experienced, how different preprocessing 
approaches might influence the final outcome. The results of this trial are presented in Table 5. 
  
Preprocessing for paper III in 2017 and the main differences from preprocessing in 2013-2015 
In 2017, the dataset was revised again with regard to the initial preprocessing steps of removing 
individuals considered as technical outliers. There were in total 168 individuals (84 case-control 
pairs) analyzed at the laboratory. In the data preprocessing step performed in 2013/2015, we marked 
11 individuals as technical outliers and removed them along with their matching case/control. We 
were thus left with 146 individuals for analysis (2013 analysis). We further removed 4 pairs in the 
2015 analysis due to unknown metastasis for the case. As our experience with the data and methods 
for outlier removal increased, we developed a standardized package for outlier removal 
(unpublished manuscript “nowaclean package”) and based on this package we decided to only 
remove four individuals as technical outliers (along with their match). The 2017 data is also based 
on a more recent update from the Cancer Registry with cancer information through 31.12.2015. For 
these data, one case with two diagnoses was identified and removed along with its matching control 
making a data set for analysis consisting of 158 individuals (79 case-control pairs). The other main 
difference between the data from 2013/2015 and 2017 is that for the former data the chips are 














Table 5. “Behind the scenes” of the gene expression analysis. First alternative analysis approaches performed 
2013-2015 
  “All models are wrong, but some are useful” (George Box, 1979) 
Preprocessing, year, main 
steps 





Corrected for background 
noise using the normal-
exponential model 
 





Mapped probes to genes  
 
Data ready for analysis 
contained 146 individuals (73 
case-control pairs) and 9327 











● Unsupervised analysis to identify 
whether there is difference between 
cases and controls in regard to 
expression of most variable genes 
 
 
● Paired analysis using global test to 
identify which variables are associated 
with blood GE globally; 
 
 
● Paired linear supervised analysis (top 
50 and top 100 genes) to identify 
single genes differently expressed 
between cases and controls; 
 
 
● Gene set enrichment analysis (GSEA) 
(among top 50 and top 100 genes). 




GSEA revealed 1 pathway, 





This finding led to development 
of additional direct analysis of 
sphingolipids in blood samples. 
This is an ongoing project. 
2015 
 
Corrected for background 
noise using the normal-
exponential model 
 
Normalized using quantile 
normalization on original scale 
level 
 
Variance stabilized using log2-
transformtion 
 
Removed 4 case-control pairs 
where the information on 
metastasis stage from the 





Probes were then translated to 
genes using function “nsFilter” 
 
Saved data of size 138 x 9327 
 
The main difference from 
preprocessing in 2013:  
 
1)data is normalized using 
quantile normalization 
 
2)We have removed 4 cases 
with unknown metastasis stage, 
along with matching controls  
GSEA revealed 2 pathways, 
which were borderline 
statistically significant and just 
in subgroup analysis (in women 
with BMI < 25): 
 
Pathways related to altered 
cholesterol and insulin 
metabolism. 
 
These findings required 
additional confirmation and 
direct measuring of cholesterol 
and insulin metabolites in blood 




6. DISCUSSION OF THE MAIN RESULTS  
 
Paper I 
“More coffee, please…” 
Investigating association between coffee consumption and EC risk has received an increased 
interest in epidemiology during the last decades. The possible favorable effect of this popular 
beverage on potential protection against EC lead to increased number of conducted studies and 
multiple discussions of any further opportunities for public health implications. There are several 
proposed biologicals pathways lying behind the inverse association between coffee consumption 
and EC risk. Coffee is a source of many antioxidants and compounds that have anti-mutagenic 
properties. Among them are caffeine, phenol compounds, isoflavones, chlorogenic acids, diterpenes 
and various additional substances like melanoids, ferulic and coumaric acids that are further 
produced during the steps of coffee preparation (177). As it was highlighted in paper I, the level of 
exposure to different active substances in coffee highly depends on several conditions such as 
brewing method, choice of coffee beans and phase of administration (251, 252). All these 
compounds are proposed to take part in regulation of hormonal metabolism through increasing the 
level of circulating sex-hormone-binding globulin (SHBG) and prevention of hyperinsulinemia by 
increasing the level of adiponectin (177). Moreover, many of the bioactive compounds in coffee are 
known for their antioxidant effects and prevention of DNA damage (253). 
In Norway, coffee is the second most consumed drink after the water (254). Despite 
representing only the 0.7% of the world’s population, Norway cover 5.5% of the world’s coffee 
import (255). The fact that Norway takes one of the leading places in daily consumption of high 
amounts of coffee initiated the interest of investigating the effect of coffee on different cancer types 
in NOWAC Study. Our main findings pointing towards overall inverse association between coffee 
consumption and EC risk, and in addition, stronger effect in current smokers and women with 
higher BMI are in accordance with both previous reports (175, 176, 256) and recently published 
studies (177, 178, 257). It is of note, that the analysis for paper I was conducted during the period 
with high publication rates of analogues reports that found a significant decreased risk in EC within 
consumption of already 3-4 cups of coffee. In this context, reporting a protective effect within 8 or 
more cups of coffee was one of the challenging issues. Our study provides the results based on a 
population that historically had a high coffee consumption. Thus, proposing the hypothesis that in 
such populations, heavy drinking of this beverage might epigenetically, generation by generation 
alter the metabolic mechanisms involved in the association of coffee consumption and cancer. 
Moreover, one of the main focuses of this paper was to investigate whether the studied association 
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is different according to brewing method, although we were not able to show significant results in 
these subgroup analyses. Moreover, in our study we have not done any repeated measurements and 
therefore, can base our conclusions just on the consumption reported at baseline. Later report from 
NOWAC by Lukic et al (258) investigating lung, ovarian, colorectal and breast cancer, showed that 
proportion of high moderate consumers (3-7 cups per day) and heavy consumers (> 7 cups per day) 
decreased during the follow-up. In addition, as it was mentioned earlier we did not have information 
on other sources of bioactive compounds that are found in coffee and that are proposed to have a 
protective effect against EC. However, in spite of the mentioned limitations, we have a solid 
evidence to consider our findings to be reliable as several meta-analysis that were published later on 
confirmed our main findings (178, 257) showing a consistent protective effect of coffee 
consumption, which is especially beneficial for women with BMI more than 25 kg/m2.  
 
Paper II  
“To menstruate or not, that is the question…” 
The women’s natural menstrual lifespan starts from menarche, interrupts by pregnancies and 
breastfeeding periods, and end ups with menopause. In addition, during the whole life, woman’s 
body goes through myriad changes influenced by numerous exposures that alter hormonal 
environment. All these factors contribute in different extent to changings in lifetime exposure to 
natural estrogen and progesterone in hormonal imbalance, and therefore might then contribute to 
endometrial carcinogenesis. Possible long-term consequences of each single reproductive factor 
differs substantially between each other and varies between individuals, making investigating of 
several factors together especially challenging.  
In paper II we observed a significant increase in risk with more years of menstruation during 
the lifetime on a population level, suggesting that LNYM might be used as a measure of collective 
effect of hormone-related factors during the reproductive period. Several epidemiologic studies 
have investigated the impact of total number of years of menstruation or number of menstrual 
cycles on hormone-depended conditions, including cancer (93, 259-261). However, few studies 
have previously looked at these associations in relation to cancer uteri. Among them, two case-
control studies examined this association using a number of natural cycles as a core variable 
combining the key reproductive and menstrual features (116, 118). One of them, showed a 56% 
greater risk in EC in women who had a median number of cycles during the lifespan compared to 
those with less than median (6), however, this study was limited by moderate sample size and 2-
groups analysis without showing a trend. To the best of my knowledge, only 2 prospective studies 
has previously investigated association between number of years of ovulation and duration of 
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menstruation span in relation to cancer uteri (98, 106). Although they both showed increased risk, 
they also had several methodological limitations. Regardless the huge heterogeneity between 
existing studies, the findings related to association between cumulative effect of reproductive 
factors and EC risk largely overlap with each other and with our findings in paper II as well, 
regardless whether years of menstruation or numbers of cycles has been used as a composite 
variable. 
The mechanisms lying behind this association are indeed very complex and not well 
understood. First and the most logic mechanism related special to EC and LNYM is connected to 
monthly mechanic shedding and removal of endometrial cells that are potentially malignant. 
Another mechanism, which is proposed to be common for many estrogen-dependent diseases, 
including cancer, is linked to so-called “estrogen window hypothesis” (262). The proliferation of 
endometrial cells is increased during the longest phase of the cycle-follicle phase. And as more 
cycles/menstruations woman has, the longer cumulative period of estrogen stimulation with 
inadequate opposed action of progesterone she gets. This could explain why earlier menarche and 
later menopause are so strong risk factors for EC. They are indeed both also linked to anovulatory 
cycles. Findings supporting “hormonal hypothesis” are linked to association between number of 
cycles/menstruations and the level of androstendione, an estrogen precursor of estrogen, at 
menopause (107) and with sex-hormone binding globulin levels (113). In addition, many studies 
have also pointed out that total menstrual lifespan is crucial and fundamental not only for the 
reproductive function but for development of many diseases that woman gets later in life. More and 
more reports are devoted to effects of so-called “ovarian aging”, proposing a hypothesis that 
predisposition to some of the health conditions in women like for example, obesity, cardio-vascular 
diseases, hormone-dependent cancers are attributed to timing of start or end of both menarche and 
menopause (Figure 21) (263). 
 





Paper III (testing hypotheses obtained in paper I and paper II) 
“The truth is out there…” 
This paper attempted to build up the disciplinary bridge between classic epidemiology and 
molecular biology with a future potential approaches towards further implication into clinical 
studies. As it was highlighted in paper III, we were limited by a sample size and therefore most 
probably due to this reason were not able to catch up many statistically significant gene signatures 
related to coffee consumption, OC use and comparably not many significant findings related to 
BMI. In addition, in spite of so obvious strong association between LNYM and EC showed in paper 
II, we have not got significant results neither related to LNYM nor to age at menopause. Although, 
among of the genes that were significant, when LNYM variable has been tested, was for example, 
gene 13q34, which is known to be proposed as one of the “genetic markers” of age at menopause 
(264). Further then, our observation of significant enrichment of 
“REACTOME_HYALURONAN_METABOLISM” gene set (FDR 20%) in OC users among cases 
is in line other studies, demonstrating the relevance the hyaluronan metabolism in EC progression 
(265, 266). Therefore, monitoring of hyaluronan acid in the blood of women using OC might be a 
valuable tool in EC screening. Of course, we cannot draw any conclusions based on the single genes 
or gene set with low level of significance, but in my opinion, such a coincidence, could give us a 
hope that, indeed, these signatures can be relevant, but statistical significance was hampered by 
sample size. At the same time, few observations related to OC use might be also explained by short-
term effect of OC on gene signatures after its discontinuation. Another interesting aspect related to 
LNYM and age at menopause is our initial expectations to get any gene signatures related to the age 
at menopause in order to reveal what is the central component in LNYM that may explain the whole 
association. Few studies, that used analogue composite variables like we did in paper II, attempted 
to speculate, if among factors summarized there, there are any leading ones. Some studies, proposed 
that the age at menopause might be a decisive component of lifetime menstruation span (118). Age 
at menarche and age at menopause, are two factors that affect the length of woman’s lifetime 
menstruation span. At the same time, both of them separately of each other, are strongly related to 
EC risk. Indeed, older age at menarche is associated with a shortening of menstruation span and 
decreased risk of EC due to later initiation of ovulatory cycles and start of excessive exposure to 
estrogens. At the same time, later age at menopause can also prolong the lifetime of menstrual 
activity and exposure to estrogens, and therefore increase EC risk.  We also attempted to check how 
these two variables might probably affect the association between LNYM and EC risk (unpublished 
results related to paper II). We found significant correlation coefficients both between LNYM and 
age at menarche or age at menopause (-0.21 and 0.41 accordingly). However, further analysis using 
Fisher r- to z-transformation test showed that correlation between age at menopause and LNYM 
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stronger than correlation between LNYM and age at menarche, supporting the hypothesis that it is 
more hazardous to get additional menstruations/cycles closer to the end of menstruation span rather 
than at the beginning. Indeed, it has been already shown the closer to menopause, the cycles are 
more often anovulatory and the qualitative characteristics of menstruations are substantially 
changed due to huge hormonal changes (267). Nevertheless, this hypothesis should be interpreted 
with caution due to existed inconsistence and controversy regarding independent impact of each of 
the factors on the cumulative risk of LNYM. Moreover, in paper III, the gene signatures related to 
both LNYM and age at menopause were unexpectedly weak in comparison to parity. At the same 
time, even though we had so limited sample size we found significant association between 
increased number of pregnancies and expressional profile in cancer-free controls. So, what is really 
causation of what? Is it then parity and pregnancies that shift the whole trajectory of association 
with LNYM? It is obvious that there is indeed interplay of many factors. However, such findings 
related to parity together with previously mentioned hypotheses proposing predisposition of many 
diseases by increased number of cycles/menstruations, prove the evolutionary hypotheses that a 
long menstrual history can have logic dangerous consequences for women. Indeed, many 
“evolution-orientated” studies propose that menstrual cycles and parity are two conflicting events in 
women’s life. They believe that human endometrium is “designed” first of all to receive and nourish 
blastocyst, and menstruation is a just a result of unsuccessful reproductive cycle. Therefore, they 
postulate that excessive number of menstrual periods is not a normal event, calling a menstrual 
cycle “a culprit”, “derivative”, “by-product”, “a side effect” as neither the brain, breast, the ovary 
nor the uterus were developed by nature to undergo each month powerful hormone fluctuations for 
so many years. They also state that as evolutionary consequences of not using uterus for its main 
purpose, childbearing, modern women get increasing number of menstruation- and bleeding-related 
diseases like endometriosis, myoma uteri, endometrial polyps and fibroids. Indeed, inverse 
association between endometriosis and parity along with inverse association between fibroids and 
parity are extensively studied and confirmed by numerous studies (268). 
 The importance and pure natural origin of relationship between the lifetime number of 
periods/parity and estrogen-dependent cancers has been already shown by studies investigating the 
incidence of hormonal malignancies among women in indigenous populations (269). More 
industrial style of life through the years affect the women’s menstrual pattern as well. Indeed, 
already in contrast to their foremothers, the modern women experience earlier age at menopause, 
later age at first birth, fewer pregnancies, fewer months of breastfeeding and later age at 
menopause. As a result, the number of periods over the life increases from about 160 to more than 
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400 (270), indicating that lifestyle and reproductive factors interplay and could attenuate the effect 
of each other. 
Our findings related to parity in controls are in accordance to the recently accepted paper 
from NOWAC where it has been demonstrated a linear decrease in BC risk after each full-term 
pregnancy independent on other risk factors and marked differences in gene expression between BC 
cases and cancer-free controls (paper in press). Gene set enrichment analysis revealed significant 
enrichment of immunologic gene sets among controls. The authors outlined a novel theory about 
pregnancy-associated long-lasting protective properties of the immune system hampering BC 
development later in life, which was recently confirmed by an experimental study (271). Moreover, 
in another preliminary analysis (work in progress) we have tested significant genes and gene sets 
from BC on endometrial and ovarian datasets and found great overlap between BC and EC and no 




7. MAIN CONCLUSIONS 
The thesis presents the results linked to the best described and known factors of EC risk. However, 
given the fact that endometrial carcinogenesis is a very complex process, we cannot rule out the 
possibility of influence of other confounders that we have not taken into account. Moreover, when 
comparing our findings to other studies especially in the future, it is important to consider that the 
obtained results are based on the exposures and life-style patterns women had 30-50 years ago. On 
the contrary, we believe that findings related to reproductive and menstrual factors should be more 
close to the real situation as during these periods women were not that much exposed to the huge 
variety of “artificial hormone modification factors” as modern women.  
 
The main conclusion based on the papers are the following: 
 
1. High coffee intake independently on brewing method might be beneficial for EC prevention, 
especially for women with high BMI.  
 
2. Elevated LNYM increases EC risk among postmenopausal women and can be used as an 
important tool that represents the cumulative effect of several risk factors and predict EC 
risk at a population level.  
 
3. Parity status has a major impact on immune gene expression in the blood of healthy women 




8. FUTURE PERSPECTIVES 
 
Coffee consumption and EC risk 
Although epidemiological findings provide evidence of beneficial health effects of coffee on EC 
risk, before any clinical recommendations could be proposed, further large population-based studies 
need to confirm these findings. In spite of our negative results in possible risk difference linked to 
the brewing methods, analogue large population-based studies are very sparse. Hence, it is 
important to try to investigate the separate effect of proposed bioactive compounds, taking into 
account other sources of diet that could have contained these components. 
 
Self-reported information on important confounders like BMI, MHT and smoking should be better 
validated 
Thus, other measurements of adiposity are required in identifying the women who at risk of 
developing of EC. Taking into account that women with the highest BMI were not the biggest 
subgroup in all three presented papers, it will be essential to reproduce our findings using BMI-
values measured by more accurate methods. This is also relevant for validation of group “former 
smokers” and “former MHT users”. In addition, more precise information about type, duration of 
smoking along with type of MHT and duration of use are preferable. 
 
LNYM is an index of measuring the total estrogen exposure 
As it was mentioned earlier, the main challenge in analogue studies is comparison as there is still a 
big methodological heterogeneity in both how the main multiple variable was constructed, and in 
number of covariates available for. Thus, additional studies, using the uniform algorithm for 
calculation of core variable, which in addition have a greater variety of variables available for 
adjustment analysis, are required in order to make an adequate comparison between the studies. 
 
Gene expression 
Our epidemiologic and preliminary findings from gene expression analysis should be verified on 
deeper functional genomic level to find underlying mechanisms that further can be exploited in the 
clinical setting. As for paper III we used only mRNA, for the next step we will use several “omics” 
approaches: 




2. DNA methylation profile (necessary for studying the cellular content of the samples stored 
in NOWAC biobank since the preservation technique used doesn’t allow to quantify cells by 
direct methods) 
3. Quantitative, qualitative and functional characterization of blood cell composition and 
serum antibodies by direct methods (for newly collected samples) 
In addition, the following improvements in gene expression analysis are generally needed: 
● Improvement and higher degree of automation of laboratory procedures will reduce the 
variance in gene expression data; 
● Standardizing of pre-analytical procedures will make it easier to compare and reproduce the 
results from analogue studies; 
 
The present PhD project had the main focus on preclinical investigation of potential 
epidemiological and genetic predictive factors that will hopefully contribute to earlier detecting the 
patients at high risk, development of the new preclinical screening models and novel targeted 
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Denne brosjyren er et hjelpemiddel for å huske riktig navn
på de hormontabletter/plaster du har brukt. 
Under bildene er det oppgitt hvilke år disse var i salg. For
noen hormontabletter/plaster finnes det esker med samme
utseende, men med ulik styrke av hormonene. Vi ber deg
tenke nøye gjennom navnet på de hormon-tabletter/plaster
du har brukt. Eldre avregistrerte preparater er ikke gjengitt
med bilder, det gjelder:
Nr. 104 Etifollin 50 mcg tabletter, solgt fra 1953-2000
Nr. 121 Menorest 37,5 mcg/24t plaster, solgt fra 1996-2002
Nr. 122 Menorest 50 mcg/24t plaster, solgt fra 1996-2002
Nr. 123 Menorest 75 mcg/24t plaster, solgt fra 1996-2002
Nr. 124 Menorest 100 mcg/24t plaster, solgt fra 1996-2002
Nr. 196 Primolut tabletter, solgt fra 1958-
Nr. 197 Perlutex tabletter, solgt fra 1960-
Nr. 199 Provera 5 og 10 mg tabletter, solgt fra 1964-
Nr. 202 Diethylstilbøstrol 0,1 mg tabletter solgt fra1980-85
Nr. 204 Primodos tabletter solgt fra 1961-74
Nr. 205 Østriol 1 mg tabletter solgt fra 1975-95
Nr. 206 Østriol 0,25 mg tabletter solgt fra 1961-83
Nr. 110
Solgt fra 1994-2002
Nr. 112 Nr. 113 Nr. 114
Solgt fra 1989 Solgt fra 1983 Solgt fra 1984




















Telefon 77 64 48 16
Nr. 106 (1mg) Solgt fra 1970
Nr. 107 (2mg)
Solgt fra 1967 

































































Estradot 100 mg 
Bilder av P-pille merker i salg 1965-2003
Nr. 7 Solgt
fra 1971
Nr. 10 Solgt fra 1980
Denne brosjyren er et hjelpemiddel for å huske riktig
navn på de p-piller du har brukt. Under bildene er det
oppgitt hvilke år p-pillene var i salg. For noen p-piller
finnes det esker med samme utseende, men med ulik
størrelse, anhengig av om de inneholder p-piller for en
eller flere måneder. Vi ber deg tenke nøye gjennom
navnet på de p-pillene du har brukt. Av noen p-piller/
merker har vi ikke bilder, det gjelder:
Nr. 1. Follistrel, solgt fra 1973–76
Nr. 2. Menokvens, solgt fra 1971–72
Nr. 3. Novokvens, solgt fra 1969–70
Nr. 5. Anovlar Mite, solgt fra 1967–69
Nr. 8. Consan, solgt fra 1968–70
Nr. 9. Delpregnin, solgt fra 1968–71
Nr. 14. Kombikvens, solgt fra 1971–75
Nr. 20. Micronor, solgt fra 1971–79
Nr. 22. Norlestrin, solgt fra 1965–80
Nr. 23. Nyo-Kon, solgt fra 1968–70
Nr. 26. Ortho-Novin Mite, solgt fra 1968–72
Nr. 39. Implanon, solgt fra 2002-
Nr. 11 Solgt fra 1969





Nr. 17 Solgt fra 1985
Nr. 16 Solgt fra 1965
Nr. 15 Solgt fra 
1966-72
Nr. 4 Solgt fra 1965-68
Nr. 13 Solgt fra 1978










Nr. 36 Solgt fra 1981
Nr. 21 Solgt fra 1971-79
Nr. 27 Solgt fra 1965-71
Nr. 24 Solgt fra 1971-81
Nr. 25 Solgt fra 1966-69
Nr. 30 Solgt fra 1968-84
Nr. 32 Solgt fra 1969-70
Nr. 33 Solgt fra 1967-69








Nr. 18 Solgt fra 1975




Har du regelmessig menstruasjon fremdeles?   
c   Ja 
c  Har uregelmessig menstruasjon
c   Vet ikke (menstruasjon uteblitt pga. sykdom o.l.) 
c Vet ikke (bruker hormonpreparat med østrogen)
c   Nei
Hvis Nei;
        har den stoppet av seg selv? c    
        har du operert vekk eggstokkene? c
        har du operert vekk livmoren? c
        annet? c    
Alder da menstruasjonen opphørte
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KVINNER OG KREFT
Hvis du samtykker i å være med, sett kryss for JA i ruten ved siden 
av. 
Dersom du ikke ønsker å delta kan du unngå purring ved å sette 
kryss for NEI og returnere skjemaet i vedlagte svarkonvolutt.
Vi ber deg fylle ut spørreskjemaet så nøye som mulig.
Skjemaet skal leses optisk. Vennligst bruk blå eller sort penn. 






med østrogen i overgangsalderen
Har du noen gang brukt
østrogentabletter/plaster? Ja c Nei c
Hvis Ja; hvor mange år har du brukt 
østrogentabletter/plaster i alt?                                                                                                    
Har du noen gang vært gravid? Ja c Nei c
Hvis Ja; hvor mange barn har du født i alt
Hvor gammel var du ved siste fødsel?
Overgangsalder
Graviditeter, fødsler og amming
UTFYLLENDE SPØRSMÅL TIL ALLE SOM  HAR BRUKT  
PREPARATER MED ØSTROGEN I FORM AV TABLETTER 
ELLER PLASTER FRA 1998 OG FREM TIL I DAG.
Har du svart «ja», ber vi deg utdype dette nærmere ved 
å svare på spørsmålene nedenfor. For hver periode med 
sammenhengende bruk av samme hormonpreparat håper vi 
du kan si oss hvor gammel du var da du startet, hvor lenge 
du brukte det samme hormonpreparatet og navnet på dette. 
Dersom du har hatt opphold eller skiftet merke skal du bes-
vare spørsmålene for en ny periode. Dersom du ikke husker 
navnet på hormonpreparatet, sett «usikker». For å hjelpe deg 
til å huske navnet på hormonpreparatene ber vi deg bruke 
den vedlagte brosjyre som viser bilder av hormonpreparater 
som har vært solgt i Norge. Vennligst oppgi også nummer på 






           Alder         Brukt samme                                 Navn på hormon-
          ved         hormontablett/                                   tablett/plaster/
         start               plaster/                                          (se brosjyre) 
                       sammenhengende
                                fra 1998                                                          
                                år          måned             Nr.                                    Pe
rio
de
Har du brukt p-piller eller  
minipiller?      Ja c Nei c
Hvis ja, hvor mange år
har du brukt p-piller i alt? 
Bruker du p-piller nå? Ja c Nei c
  P-pillebruk
  Østrogenpreparat til lokal bruk i skjeden
Har du noen gang brukt østrogen-
krem/stikkpille?.............................................................................................Ja c  Nei c
Hvis Ja;
bruker du krem/stikkpille nå?...................................Ja c  Nei c
Hvor gammel var du første gang du 
brukte østrogentabletter/plaster?                                                                                           
 
Bruker du tabletter/plaster nå? Ja c Nei c
Jeg samtykker i å delta i             JA  
spørreskjemaundersøkelsen    NEI   
Sykdom
                                                               
Kreft c c




Sukkersyke (diabetes) c c
Depresjon (oppsøkt lege) c c
Hypothyreose/lavt stoffskifte c c





Har du eller har du hatt noen av følgende sykdommer?
(sett ett eller flere kryss)
  Andre legemidler
Bruker du noen av disse legemidlene daglig nå?
Fontex, Fluoxetin Ja c  Nei c
Cipramil, Citalopram, Desital Ja c  Nei c
Seroxat, Paroxetin Ja c  Nei c
Zoloft Ja c  Nei c
Fevarin Ja c  Nei c
Cipralex Ja c  Nei c
Hvis Ja; hvor lenge har du brukt 
dette legemidlet sammenhengede?
Har du benyttet noen av disse 
legemidlene tidligere? Ja c  Nei c
Hvis Ja; hvor lenge har du benyttet 
disse legemidlene i alt? 
Måneder           År
                         År
  Selvopplevd helse
Oppfatter du din egen helse som; (Sett ett kryss)
Meget god c                God c       Dårlig c        Meget dårlig c
Hvor høy er du?(i hele cm) 
Hvor mye veier du i dag?(i hele kg) 
Hvor mye veide du da du var 18 år?(i hele kg)
Høyde og vekt
Kroppstype i 1. klasse. (Sett ett kryss)
Veldig tynn c  Tynn c   Normal c  Tykk c Veldig tykk c
For følgende tilstander ber vi deg krysse av for hvilket år 
tilstanden oppsto første gang.
                                          før 98  98     99 00     01     02     03
Muskelsmerter (myalgi)      c  c  c c  c  c  c 
Fibromyalgi/Fibrositt                        c  c  c c  c  c  c 
Kronisk tretthetssyndrom  c  c  c c  c  c  c 
Ryggsmerter ukjent årsak c  c  c c  c  c  c
Nakkeslengskade               c  c  c c  c  c  c
Osteoporose (b.skjørhet)       c  c  c c  c  c  c
Brudd 
Underarmen (håndledd)       c  c  c c  c  c  c 
Lårhalsen                               c  c  c c  c  c  c 
Ryggvirvel (kompresjon)      c  c  c c  c  c  c 
Har du noen gang brukt 
hormonspiral (Levonova)? Ja c Nei c
Hvis Ja; hvor mange hele år har du brukt 
hormonspiral i alt? 
Hvor gammel var du første gang du fikk 
innsatt hormonspiral?    
Bruker du hormonspiral nå? Ja c  Nei c
Hormonspiral
                                     Antall sigaretter pr. dag                         
                      0          1-4        5-9     10-14     15-19    20-24      25+
                     c    c   c   c    c    c    c  
Har du i løpet av livet røykt mer enn 
100 sigaretter til sammen? Ja c  Nei c
Røykevaner
Hvis Ja, ber vi deg  fylle ut for de siste fem årene hvor 
mange sigaretter du i gjennomsnitt røykte pr. dag i 
denne perioden.
Hvor gammel var du da du tok din 
første sigarett?
Røyker du daglig nå? Ja c  Nei c  
Hvis Nei, hvor gammel var du da du sluttet?
Røykte noen av dine foreldre
da du var barn? Ja c  Nei c
Hvis Ja, hvor mange sigaretter røykte de 
til sammen pr. dag? (antall)                             
Har noen nære slektninger hatt brystkreft? 
Datter                                                      c c c
Mor                                                            c c c
Søster                                                    c c c
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Brystkreft i nærmeste familie









Vi ber deg angi din fysiske aktivitet etter en skala fra 
svært liten til svært mye ved 14 års alder, ved 30 års 
alder og i dag. Skalaen nedenfor går fra 1-10. Med 
fysisk aktivitet mener vi både arbeid i hjemmet og i 






















1 2 3 4 5 6 7 8 9 10
Mammografiundersøkelse
Har du vært til undersøkelse
av brystene med mammografi Ja c  Nei c
Hvis Ja;
hvor gammel var du første gangen? (hele år) 
Hvor mange ganger har du vært undersøkt?
-etter invitasjon fra Mammografiprogrammet 
-etter henvisning fra lege 
-uten henvisning fra lege 
Hvor mange timer pr. dag i gjennomsnitt går eller 
spaserer du utendørs?
                          sjelden/     mindre     1/2-1 time   1-2 timer  mer enn
                             aldri    enn 1/2 time                                       2 timer
Vinter              c                           c                              c                            c                      c 
Vår                   c                           c                              c                            c                      c
Sommer          c                           c                              c                            c                      c
Høst                c                           c                              c                            c                      c
Aktivitet            Vinter              Vår           Sommer       Høst
For hver av følgende aktiviteter du deltar i, 
ber vi deg oppgi hvor mange minutter pr. dag 
du bruker i gjennomsnitt til hver av aktivitetene.
Hvor mange hele timer pr. dag bruker du 






Hvor mange trapper (hele etasjer) går 
du i gjennomsnitt pr. dag
Kosthold
Påvirker noen av følgende forhold kostholdet ditt? 
(sett gjerne flere kryss)





Vi er interessert i å få kjennskap til hvordan kostholdet 
ditt er vanligvis. Kryss av for hvert spørsmål om hvor 
ofte du i gjennomsnitt siste året har brukt den aktuelle 
matvaren, og hvor mye du pleier å spise/drikke hver 
gang. 
c Er vegetarianer/veganer
c Prøver å gå
     ned i vekt
Hvor mange glass melk drikker du vanligvis av hver 
type? (Sett ett kryss pr. linje)
                                             aldri/      1-4 pr.    5-6  pr.  1  pr.    2-3 pr.       4+ 
                                            sjelden      uke         uke      dag       dag      pr.dag
Helmelk (søt, sur)         c    c    c   c    c   c
Lettmelk (søt, sur)       c    c    c   c    c   c
Ekstra lettmelk                    c    c    c   c    c   c





     mat
Hvor mange glass appelsinjuice, saft og brus drikker 
du vanligvis? (Sett ett kryss for hver linje)
                                                    aldri/     1-3 pr.  4-6 pr.   1 pr.    2-3 pr.  4+ pr.  
                                                 sjelden     uke       uke       dag      dag      dag
Appelsinjuice                   c   c  c  c   c   c
Annen juice                      c   c  c  c   c   c
Saft/brus med sukker  c   c  c  c   c   c
Saft/brus sukkerfri        c   c  c  c   c   c
Makrell i tomat,          c    c    c   c    c   c 
røkt makrell
Kaviar                                 c    c    c   c    c   c
Sild/Ansjos                     c    c    c   c    c   c
Laks (gravet/røkt)       c    c    c   c    c   c
Annet fiskepålegg      c    c    c   c    c   c
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Hvor mange skiver brød/rundstykker og knekkebrød/
skonrokker spiser du vanligvis? 
(1/2 rundstykke = 1 brødskive)  (Sett ett kryss for hver linje)
                                             aldri/      1-4 pr.    5-7  pr.    2-3 pr.     4-5 pr.       6+ 
                                            sjelden      uke         uke         dag         dag         pr.
                                                                                                                            dag
 Grovt brød                                  c    c    c    c    c   c
 Kneipp/halvfint               c    c    c    c    c   c
 Fint brød/baguett      c    c    c    c    c   c
 Knekkebrød o.l.             c    c    c    c    c   c
                                             Aldri/      1-3 pr.    4-6  pr.     1 pr.       2-3 pr.       4+ 
                                            sjelden      uke         uke         dag         dag      pr.dag
                                                                                                                               
 
 
Syltetøy c c c c c c 
Brunost, helfet c c c c c c
Brunost,
halvfet/mager c c c c c c
Hvitost, helfet c c c c c c 
Hvitost,
halvfet/mager c c c c c c 
Kjøttpålegg,
Leverpostei c c c c c c
Rekesalat, c c c c c c
italiensk o.l. 
  
I neste spalte er det spørsmål om bruk av ulike 
påleggstyper. Vi spør om hvor mange brødskiver med 
det aktuelle pålegget du pleier å spise. Dersom du 
også bruker matvarene i andre sammenhenger enn til 
brød (f. eks. til vafler, frokostblandinger, grøt), ber vi 
om at du tar med dette når du besvarer spørsmålene.
                                        Aldri/          1            2-3         4-6          7-9        10+  
                                      sjelden    pr.uke      pr.uke     pr.uke      pr.uke     pr.uke
                                                                                                                           
På hvor mange brødskiver pr. uke har du i 
gjennomsnitt siste året spist? (Sett ett kryss pr. linje)
Hva slags fett bruker du vanligvis på brødet?
(Sett gjerne flere kryss)
c Bruker ikke fett på brødet
c Smør
c Hard margarin (f. eks. Per, Melange)
c Myk margarin (f. eks. Soft, Vita, Solsikke)
c Smørblandet margarin (f.eks. Bremyk)
c Brelett
c Lettmargarin (f. eks. Soft light, Letta, Vita Lett)
c Middels lett margarin (f. eks. Olivero, Omega)
Hvor ofte spiser du yoghurt (1 beger)? (Sett ett kryss)
c Aldri/sjelden  c 1 pr. uke
c 2-3 pr. uke c 4+ pr. uke
Dersom du bruker fett på brødet, hvor tykt lag pleier 
du å smøre på? (En kuvertpakke med margarin veier 12 gram). 
(Sett ett kryss)
c Skrapet (3 g)
c Tykt lag (12 g)
Hvor ofte spiser du kornblanding, havregryn eller 
müsli? (Sett ett kryss)
c Aldri/sjelden c 1-3 pr. uke
c 4-6 pr. uke c 1 pr. dag
Hvor mange kopper kaffe/te drikker du vanligvis av 
hver sort? (Sett ett kryss for hver linje) 
                              aldri/      1-6 pr.       1  pr. 2-3 pr.     4-5 pr.     6-7 pr. 8+
                           sjelden      uke         dag dag         dag         dag pr.dag
Kokekaffe     c    c    c c    c    c c
Traktekaffe    c    c    c c    c    c c
Pulverkaffe    c    c    c c    c    c c
Svart te         c    c    c c    c    c c
Grønn te        c    c    c c    c    c c
Hvor mange glass vann drikker du vanligvis? 
(Sett ett kryss for hver linje)
                            aldri/        1-6 pr.      1  pr.     2-3 pr.     4-5 pr.    6-7 pr.      8+
                         sjelden        uke        dag        dag         dag        dag     pr.dag
Springvann/  c    c    c c    c    c c
flaskevann
Bruker du følgende i kaffe eller te:
  Kaffe      Te
Sukker (ikke kunstig søtstoff) c Ja c Nei c Ja c Nei
Melk eller fløte c Ja c Nei c Ja c Nei
På hvor mange brødskiver bruker du? (Sett ett kryss pr. linje)
c Godt dekket (8 g)
c Tynt lag (5 g)
Hvor ofte spiser du frukt?  (Sett ett kryss pr. linje)
Epler/pærer c c c c c c c
Appelsiner o.l. c c c c c c c
Bananer c c c c c c c
Annen frukt c c c c c c c
                             aldri/         1-3           1           2-4         5-6            1            2+ 
                            sjelden   pr.mnd.    pr.uke      pr.uke    pr.uke     pr.dag       pr.
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Hvor ofte spiser du ulike typer grønnsaker?  
(Sett ett kryss pr. linje)
Gulrøtter c c c c c c c 
Kål c c c c c c c 
Kålrot c c c c c c c 
Brokkoli/blomkål c c c c c c c
Blandet salat c c c c c c c 
Tomat c c c c c c c 
Grønnsak-
blanding (frossen) c c c c c c c
Løk c c c c c c c
Andre grønn- 
saker c c c c c c c
                             aldri/         1-3           1             2             3            4-5          6-7 
                            sjelden   pr.mnd.    pr.uke     pr.uke    pr.uke     pr.uke       pr.
                                                                                                                            uke
Hvor mange poteter spiser du vanligvis (kokte, stek-
te, mos)? (Sett ett kryss)
Hvor ofte bruker du ris og spaghetti/makaroni? 
(Sett ett kryss pr. linje)                                                        aldri/      1-3 pr.      1 pr.        2 pr.         3+
                                                      sjelden     mnd.        uke          uke       pr.uke
Ris c c c c c
Spagetti, makaroni, nudler c c c c c
Hvor ofte spiser du grøt ? (Sett ett kryss pr. linje)
Fisk
Vi vil gjerne vite hvor ofte du pleier å spise fisk, og ber 
deg fylle ut spørsmålene om fiskeforbruk så godt du 
kan. Tilgangen på fisk kan variere gjennom året. Vær 
vennlig å markere i hvilke årstider du spiser de ulike 
fiskeslagene.
                                        aldri/    like mye    vinter       vår      sommer     høst
                                      sjelden  hele året
Torsk, sei, hyse, lyr c c c c c c
Steinbit, flyndre, uer c c c c c c
Laks, ørret c c c c c c
Makrell c c c c c c
Sild c c c c c c
Annen fisk c c c c c c 
                                                        aldri/          1           2-3            1            2+ 
                                                      sjelden  pr. mnd.  pr. mnd.   pr. uke    pr. uke
                                            
Kokt torsk,  c c c c c
sei, hyse, lyr 
Stekt torsk,  c c c c c
sei, hyse, lyr 
Steinbit,  c c c c c
flyndre, uer 
Laks, ørret c c c c c
Makrell c c c c c
Sild c c c c c
Annen fisk c c c c c 
Med tanke på de periodene av året der du spiser fisk, 
hvor ofte pleier du å spise følgende til middag?
(Sett ett kryss pr. linje)
Dersom du spiser  fisk, hvor mye spiser du vanligvis 
pr. gang? (1 skive/stykke = 150 gram)
Hvor mange ganger pr. år spiser du fiskeinnmat?
(Sett ett kryss pr. linje)
Dersom du spiser fiskelever, hvor mange spise-
skjeer pleier du å spise hver gang? (Sett ett kryss)
                                                              0         1-3       4-6      7-9      10+
Rogn c c c c c
Fiskelever c c c c c
c 1 c 2 c 3-4 c 5-6 c 7+
                                                        aldri/        1 pr.      2-3 pr.       1 pr.         2+
                                                      sjelden     mnd.      mnd.         uke       pr. uke
Fiskekaker/pudding/boller c c c c c
Plukkfisk/fiskegrateng c c c c c
Frityrfisk/fiskepinner c c c c c
Hvor ofte bruker du følgende typer fiskemat?
(Sett ett kryss pr. linje)
c 1-4 pr. uke
c 5-6 pr. uke c 1 pr. dag c 2 pr. dag
c 3 pr. dag c 4+ pr. dag
c Spiser ikke/spiser sjelden poteter
Kokt fisk (skive) c 1 c 1,5 c 2 c 3+
Stekt fisk (stykke)
For de grønnsakene du spiser, kryss av for hvor mye 
du spiser hver gang. (Sett ett kryss for hver sort)
Gulrøtter          c 1/2 stk    c 1 stk   c 1 1/2 stk c 2+ stk.
Kål                     c 1/2 dl      c 1 dl     c 1 1/2 dl c 2+ dl
Kålrot                c 1/2 dl      c 1 dl     c 1 1/2 dl c 2+ dl
Brokkoli/
blomkål             c 1-2 buketter  c 3-4 buketter   c 5+ buketter
Blandet salat c 1 dl        c 2 dl     c 3 dl       c 4+ dl
Tomat               c 1/4 stk    c 1/2 stkc 1stk      c 2+ stk
Grønnsak-
blanding         c 1/2 dl     c 1 dl     c 2 dl       c 3+ dl
                                        aldri/        1 pr.       2-3 pr.      1 pr.         2-6          1+ 
                                      sjelden     mnd.       mnd.        uke       pr. uke       pr.  
                                                                                                                        dag
Risengrynsgrøt c c c c c c
Annen grøt c c c c c c
(havre o.l.)
Ris, spaghetti, grøt, suppe
c 1 c 1,5 c 2 c 3+
Hvor ofte spiser du suppe? 
(Sett ett kryss pr. linje)                                                        aldri/      1-3 pr.      1 pr.        2 pr.         3+
                                                      sjelden     mnd.        uke          uke       pr.uke
Som hovedrett c c c c c
Som forrett, lunsj
eller kveldsmat c c c c c
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I tillegg til informasjon om fiskeforbruk er det viktig å 
få kartlagt hvilket tilbehør som blir servert til fisk. 
Hvor ofte bruker du følgende til fisk? 
                                                        aldri/        1 pr.      2-3 pr.       1 pr.         2+
                                                      sjelden     mnd.      mnd.         uke       pr. uke
Smeltet/fast smør c c c c c
Smeltet/fast margarin/fett c c c c c
Seterrømme (35%) c c c c c
Lettrømme (20%) c c c c c
Saus med fett (hvit/brun) c c c c c
Saus uten fett (hvit/brun) c c c c c
Hvor ofte spiser du bakevarer som boller, kaker, 
wienerbrød eller småkaker (Sett ett kryss pr. linje)
                                        aldri/      1-3 pr.       1 pr.      2-3 pr     4-6 pr.        1+
                                      sjelden     mnd.        uke         uke          uke       pr.dag
Gjærbakst (boller o.l.) c c c c c c
Wienerbrød, kringle c c c c c c
Kaker  c c c c c c
Pannekaker c c c c c c
Vafler c c c c c c
Småkaker, kjeks c c c c c c
Lefser, lomper c c c c c c
Hvor mye is spiser du vanligvis pr. gang? (Sett ett kryss)
                                                        aldri/          1           2-3            1           2+
                                                      sjelden   pr.mnd.   pr.mnd.    pr.uke     pr.uke
Kjøtt
Hvor ofte spiser du følgende kjøtt- og fjærkreretter? 
(Sett ett kryss for hver rett)
Steik (okse, svin, får) c c c c c
Koteletter c c c c c
Biff c c c c c
Kjøttkaker, karbonader c c c c c
Pølser c c c c c
Gryterett, lapskaus c c c c c
Pizza med kjøtt c c c c c
Kylling c c c c c
Bacon, flesk c c c c c
Andre kjøttretter c c c c c
Hvor mange egg spiser du vanligvis i løpet av en 
uke?(stekte, kokte, eggerøre, omelett) (Sett ett kryss)
c 0 c 1 c 2 c 3-4
c 5-6 c 7+
Hvor ofte spiser du iskrem? (til dessert, Krone-is osv.)
Sett ett kryss for hvor ofte du spiser iskrem om somme-
ren, og ett kryss for resten av året
                                                        aldri/        1 pr.      2-3 pr.       1 pr.         2+
                                                      sjelden     mnd.      mnd.         uke       pr.uke
Om sommeren c c c c c
Resten av året c c c c c
c 1dl c 2 dl c 3 dl c 4+ dl
c Aldri/sjelden c 1 pr. mnd. c 2-3 pr. mnd. c 1 pr. uke
c 2-3 pr. uke c 4+ pr. uke
Hvor ofte spiser du reinkjøtt?
Hvor stor mengde pleier du vanligvis å spise av de 
ulike rettene? (Sett ett kryss for hver linje)
Fiskekaker/pudding/boller (stk.)  c 1     c 2      c 3     c 4+
(2 fiskeboller=1 fiskekake)
Plukkfisk, fiskegrateng (dl)       c 1-2  c 3-4  c 5+
Frityrfisk, fiskepinner (stk.)       c 1-2  c 3-4  c 5-6  c 7+
For de ulike typene tilbehør du bruker til fisk, vær 
vennlig å kryss av for hvor mye du vanligvis pleier å 
spise. 
Smeltet/              c 1/2     c 1    c 2      c 3  c 4+
fast smør (ss)       
Smeltet/              c 1/2     c 1    c 2      c 3  c 4+
fast margarin (ss)
Seterrømme (ss)  c 1/2     c 1    c 2      c 3  c 4+
Lettrømme (ss)     c 1/2     c 1    c 2      c 3  c 4+
Saus med fett (dl) c 1/4     c 1/2 c 3/4  c  1 c 2+ 
Saus uten fett (dl) c 1/4    c 1/2 c 3/4  c 1  c 2+ 
Dersom du spiser følgende retter, oppgi mengden du 
vanligvis spiser:  (Sett ett kryss for hver linje)
Steik (skiver)          c 1        c 2    c 3       c 4 c 5+
Koteletter (stk.)      c 1/2     c 1    c 1,5    c 2+
Kjøttkaker, 
karbonader (stk.)  c 1         c 2    c 3       c 4+
Pølser (stk. à 150g)  c 1/2     c 1    c 1,5   c 2+
Gryterett,
lapskaus (dl)         c 1-2     c 3    c 4       c 5+
Pizza m/kjøtt
(stykke à 100 g)         c 1       c 2     c 3       c 4+ 
Hvor ofte spiser du skalldyr (f. eks. reker, krabbe 
og skjell)? (Sett ett kryss)
c Aldri/sjelden c 1 pr. mnd c 2-3 pr. mnd c 1+ pr. uke
Hvilke sauser bruker du til kjøttretter og pastaretter? 
(Sett ett kryss pr. linje)                                                        aldri/        1 pr.      2-3 pr.       1 pr.         2+
                                                      sjelden     mnd.      mnd.         uke       pr. uke
Brun saus c c c c c
Sjysaus c c c c c
Tomatsaus c c c c c
Saus med fløte/rømme c c c c c
Hvor mye bruker du vanligvis av disse sausene?
Brun saus (dl)     c 1/4     c 1/2   c 3/4   c  1    c 2+
Sjysaus (dl)         c 1/4     c 1/2   c 3/4   c  1    c 2+
Tomatsaus (dl)     c 1/4     c 1/2   c 3/4   c  1    c 2+
Saus med fløte/  c 1/4     c 1/2   c 3/4   c  1    c 2+
rømme (dl)
Andre matvarer
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Bruker du tranpiller/fiskeoljekapsler? .
                                        aldri/      1-3 pr.       1 pr.     2-3 pr.     4-6 pr.      1+ pr.
                                      sjelden     mnd.        uke         uke          uke         dag 
                                                                                                                           
Potetchips c c c c c c
Peanøtter c c c c c c
Andre nøtter c c c c c c
Annen snacks c c c c c c
Hvor ofte spiser du snacks? (Sett ett kryss)
Ja c Nei c
Tran og fiskeoljekapsler
Bruker du tran (flytende)? 
                                                        aldri/      1-3 pr.      1 pr.      2-6 pr.     daglig
                                                      sjelden     mnd.        uke          uke
Om vinteren c c c c c
Resten av året c c c c c
Hvis ja; hvor ofte tar du tran?
Sett ett kryss for hver linje.
                                                        aldri/      1-3 pr.      1 pr.      2-6 pr.     daglig
                                                      sjelden     mnd.        uke          uke
Hvis ja; hvor ofte tar du tranpiller/fiskeoljekapsler?
Sett ett kryss for hver linje.
Hvilken type tranpiller/fiskeoljekapsler bruker du van-





Hvis ja, hvor ofte bruker du kosttilskudd? 
(Sett ett kryss pr. linje)
Er du totalavholdskvinne?
Hvis Nei; hvor ofte og hvor mye drakk du i
gjennomsnitt siste året? (Sett ett kryss for hver linje)
                            aldri/     1 pr.   2-3 pr.   1 pr.     2-4 pr.    5-6 pr.        1         2+ 
                           sjelden mnd.     mnd.     uke        uke         uke          pr.        pr.
                                                                                                               dag      dag
Øl (1/2 l.) c c c c c c c c
Vin (glass) c c c c c c c c
Brennevin c c c c c c c c
(drink)
Likør/Hetvin  c c c c c c c c
 (glass)
Hvor mye tran pleier du å ta hver gang?
c 1 ts. c 1/2 ss. c 1+ ss.
                                                        aldri/      1-3 pr.      1 pr.      2-6 pr.     daglig
                                                      sjelden     mnd.        uke          uke            Navn på kosttilskudd
 c c c c c
 c c c c c
 c c c c c
 c c c c c
Alkohol
Dersom du spiser sjokolade, hvor mye pleier du 
vanligvis å spise hver gang? Tenk deg størrelsen på en 
Kvikk-Lunsj sjokolade, og oppgi hvor mye du spiser i forhold til den.
 c 1/4    c 1/2     c 3/4    c 1  c 1,5   c 2+
Bruker du soyapreparater mot
plager i overgangsalderen?
Kosthold som barn
Hvor mye melk drakk du som barn hver dag? (sett ett kryss)
c drakk ikke melk  c 1-3 glass  c 4-6 glass  c 7 glass eller mer
Hvor ofte spiste du grønnsaker til middag som barn? 
(sett ett kryss)
c aldri                    c 1 gang i uken eller mer sjelden
c 2-3 ganger i uken  c 4 eller flere ganger pr. uke
Varm mat
Hvor mange ganger i løpet av en måned spiser du varm 
mat?
Til frokost                                           Til middag
Til lunsj                                               Til kvelds
Ja c Nei c
Om vinteren c c c c c
Resten av året c c c c c
Ja c Nei c
Ja c Nei c
Ja c Nei c
Hvor ofte spiste du fisk til middag som barn? (sett ett 
kryss)
c aldri                    c 1 gang i uken eller mer sjelden
c 2-3 ganger i uken  c 4 eller flere ganger pr. uke
Hvor ofte spiser du dessert? (Sett ett kryss pr. linje)
                                        aldri/        1 pr.        2-3 pr      1 pr       2-3 pr.      4+ pr.
                                      sjelden     mnd.       mnd.        uke          uke         uke
Pudding c c c c c c
sjokolade/karamell 
Riskrem, fromasj c c c c c c
Kompott, fruktgrøt,  c c c c c c
hermetisk frukt 
Jordbær (friske, frosne) c c c c c c
Andre bær (friske, frosne) c c c c c c
Hvor ofte spiser du sjokolade? (Sett ett kryss)
                                        aldri/      1-3 pr.       1 pr.      2-3 pr     4-6 pr.        1+
                                      sjelden     mnd.        uke         uke          uke       pr.dag
 
Mørk sjokolade c c c c c c 
Lys sjokolade c c c c c c
c inntil 150.000 kr. c 151.000-300.000 kr.
c 301.000-450.000 kr. c 451.000-600.000 kr.
c 601.000-750.000 kr. c over 750.000 kr.
For å kunne studere effekten av soling på risiko for 
hudkreft, ber vi deg gi opplysninger om hudfarge.
Sett ett kryss på det tallet under fargen som best 
passer din naturlige hudfarge (uten soling).
Hvor ofte bruker du følgende hudpleiemidler?  
(Sett ett kryss pr. linje)
Ansiktskrem c c c c c c c
Håndkrem c c c c c c c
Body lotion c c c c c c c
Parfyme c c c c c c c
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Til slutt vil vi spørre deg om ditt 
samtykke til å kontakte deg på nytt pr. post. 
Vi vil hente adressen fra det sentrale personregister.
Takk for at du ville delta i undersøkelsen
Er du villig til å avgi en blodprøve?
Hvor mange ganger pr. år er du blitt forbrent av solen
slik at du har fått svie eller blemmer med avflassing 
etterpå? (ett kryss for hver aldersgruppe)
Alder                      Aldri              Høyst          2-3 g.        4-5 g.      6 eller flere
                                               1 gang pr. år     pr. år        pr. år       ganger pr. år
40-49 år         c      c      c     c     c
50 + år            c      c      c     c     c
Hvor mange uker i gjennomsnitt pr. år har du vært 
på badeferie i syden eller i Norge?
Alder                      Aldri              1 uke            2-3           4-5            7 uker                                                                           uker          uker         eller mer
40-49 år         c      c      c     c       c
50 + år            c      c      c     c       c
Siste 12 mnd.   c      c      c     c       c
Hvor ofte dusjer eller bader du?
                          mer enn      1 g.       4-6 g.      2-3 g.       1 g.        2-3 g.    sjelden/ 
                          1 g. dagl.   dagl.      pr. uke    pr. uke   pr. uke    pr. mnd     aldri
                                                                                                                               
Med såpe/ c c c c c c c
shampo
Uten såpe/ c c c c c c c
shampo
Når bruker du krem med solfaktor? (sett evt. flere kryss):
Hvilken solfaktor bruker du i disse periodene?
c i påsken c i Norge eller utenfor syden
c solferie i syden c aldri
Hvor mange uregelmessige føflekker større enn 5 
mm har du sammenlagt på begge beina (fra tærne til 
lysken)? Tre eksempler på føflekker større enn 
5 mm med uregelmessig form er vist nedenfor.
c 0    c 1  c 2-3   c 4-6   c 7-12   c 13-24 c 25+
5 mm
                             aldri/         1-3           1           2-4         5-6            1            2+ 
                            sjelden   pr.mnd.    pr.uke      pr.uke    pr.uke     pr.dag       pr.
                                                                                                                            dag
Solvaner
Får du fregner når du soler deg? ................
1 2 3 4 5 6 7 8 9 10
    1         2         3         4         5         6         7         8         9        10
Hvor ofte har du solt deg i solarium?
  Alder                   Aldri    Sjelden     1 gang    2 ganger 3-4 ganger     oftere                                                            pr. mnd.   pr. mnd.    pr. mnd   enn 1 gang
                                                                                                                   pr. uke
40-49 år         c    c    c c    c     c
50+ år             c    c    c c    c     c
Siste 12 mnd.   c    c    c c    c     c
Hva er din arbeidssituasjon? (sett ett eller flere kryss)
c Arbeider heltid        c Arbeider deltid       c Pensjonist
c Hjemmearbeidende c Under utdanning   c Uføretrygdet
c Under attføring        c Arbeidssøkende
Arbeider du utendørs i
yrkessammenheng?                                             
Hvis Ja;
hvor mange timer pr. uke?          ...Sommer              ... Vinter
                        Ingen     1-4        5-9        10-14        15+
Påsken              c    c    c      c      c
I Norge eller
utenfor syden   c    c    c      c      c
Solferie i syden     c    c    c      c      c
Hvor mange personer er det i ditt hushold?
Sosiale forhold
Er du idag: (Sett ett kryss)
c gift c samboer c ugift c skilt c enke
Hvor høy er bruttoinntekten i husholdet pr. år?
Ja c Nei c
Ja c Nei c
Ja c Nei c





Du sendte i 2003 eller 2004 et utfylt spørreskjema til Institutt for samfunnsmedisin som del av den 
landsdekkende undersøkelsen ”Kvinner og kreft”. Spørsmålene var særlig rettet mot kosthold. 
Vi ønsker å studere hvilken betydning våre matvaner har for kreftutvikling hos kvinner. I følgeskrivet
til spørreskjemaet informerte vi om at en del kvinner senere ville bli forespurt om de var villig til å
avgi blodprøve. Blodprøvene vil bli avidentifisert ved ankomst Institutt for samfunnsmedisin.
Formålet med blodprøven vil være:
• Måle nivå av vitaminer, mineraler og andre stoffer i blodet som kan settes 
i forbindelse med kostholdet.
• I fremtiden kunne studere de såkalte genetiske markører dvs. egenskaper i arvestoffet 
som kan disponere for kreft.
• Teste nye ideer eller hypoteser som oppstår i fremtiden.
Det er frivillig om du vil delta. Du kan trekke deg uten begrunnelse, og du kan be om at 
opplysninger du har gitt blir slettet, uten at dette vil få konsekvenser for deg. 
Blodprøven vil kun bli benyttet til forskning og ingen resultater vil bli utlevert til deg eller 
noen andre. Blodprøven vil bli lagret i 30 år.
Ansvarlig for undersøkelsen er professor Eiliv Lund. Undersøkelsen er tilrådd av Regional komité 
for medisinsk forskningsetikk, Nord-Norge (REK NORD), og Datatilsynet har gitt konsesjon for 
oppbevaring av opplysninger. 
Fremtidige forskningsprosjekter som vil benytte de lagrete blodprøvene vil forelegges Regional
komité for medisinsk forskningsetikk, Nord-Norge (REK NORD).
Du kan finne mer informasjon om ”Kvinner og kreft”og om forskningsresultatene på våre nettsider: www.ism.uit.no/kk/
Med vennlig hilsen
Eiliv Lund Bente A. Augdal
professor dr.med. prosjektmedarbeider
"
Ønsker du ikke å delta og vil slippe påminning pr. brev ber vi deg fylle ut svar-slippen og returnere
denne sammen med utstyret tilbake til oss (forseglet utstyr må ikke åpnes).





NOWAC questionnaire that accompanies the blood samples
2005
CONFIDENCIAL
The questionnaire must be answered in connection with
the blood draw. ID:
The questionnaire MUST accompany the blood sample LAB:
I have read the information concerning the blood sample donation
and I concent to participate:
Yes
Blood draw Smoking during the past week
When was the blood sample drawn? Have you smoked during the past week?
Date (day, month) Yes
Time (hour,minute) No
If yes, how many cigarettes did you smoke
When was your latest meal before blood draw?
Yesterday
Date (day, month) Today
Time (hour,minute)
Posture during blood draw: Weight/height
Sitting What do you weigh today? kg
Laying down How tall are you? cm
Were weight and height measured at 
the doctor's office today?
Menstruation
Yes





If yes, please provide the date for the first day
of your last menstruation:
(day, month)
Medication during the past week Dietary supplements use during the past week
Have you used oral contraceptives Have you taken cod liver oil (liquid)
during the past week? during the past week?
Yes Yes
No No
If yes, please provide the date for the last tablet If yes, please provide the date for the last dose
taken: (day, month) (day, month)
How much did you take at that time?
1 teaspoon
Have you used hormone tablets/patches 1/2 tablespoon
(estrogen, gestagen) for climacteric complaints ≥ 1 tablespoon
during the past week?
Yes
No
Have you taken capsules containing
If yes, please provide the date when the last tablet cod liver oil/omega-3/fish oil during the past week?
was taken: Yes
(day, month) No
Product name: If yes, please provide the date for the last dose
Product name: (day, month)
How many capsules did you take at that time?
1
Have you used any other medication 2
during the past week? ≥ 3
Yes Product name:
No
If yes, please provide the date when the medication






(day, month) Product name:
Product name:
(day, month) Have you taken any other dietary supplements
(vitamins/minerals) during the past week?
Product name: Yes
No











Series 1-5, 8, 9
Year 1991-1992
«How many glasses of coffe do you





• 2-4 cups/week, 
• 5-6 cups/week
• 1 cup/day, 2-3 cups/day
• 4-5 cups/day
• 6-10 cups/day.
Series 11, 17, 18
Year 1996
«Do you drink coffee?»
Total coffee
Categories: almost never, 1-3 
cups/month, 1 cup/week, 2-4 
cups/week, 5-6 cups/week, 1 cup/day, 
2-3 cups/day,4-5 cups/day,6-10 
cups/day.
Series 25, 27, 30
Year 1998, 2000
«Do you drink coffee?»
Total coffee
Categories: almost never, 1-3 
cups/month, 1 cup/week, 2-4 
cups/week, 5-6 cups/week, 1 cup/day, 




«Do you drink coffee?»
Total coffee
Categories: almost never, 1-3 
cups/month, 1 cup/week, 2-4 cups/week, 
5-6 cups/week, 1 cup/day, 2-3 
cups/day,4-5 cups/day,6-10 cups/day.
Series 12-16, 19-23, 35,36
Year 1996-1997, 2003-2004
«Do you drink those coffee types?»
Boiled, Filtered, Instant
Categories: almost never, 1-6 
cups/week, 1 cup/day, 2-3 cups/day, 




«Do you drink those coffee types?»
Boiled, Filtered, Instant
Categories: almost never, 1-6 
cups/week, 1 cup/day, 2-3 cups/day, 4-
5 cups/dag, 6-7 cup/day, 8+ cups/day.
Series 34, 38, 39,42
Year 2002-2005
«Do you drink those coffee types?»
Boiled, Filtered, Instant
Categories: almost never, 1-6 
cups/week, 1 cup/day, 2-3 cups/day, 4-5 
cups/dag, 6-7 cup/day, 8+ cups/day.
Appendix 8. Modification of coffee categories for analysis based on available information from NOWAC questionnaires.
Collapsing of the categories with low consumption from all questionnaires
(1 cup/day, 5–6 cups/week, 2–4 cups/week, 1–6 cups/week, 1 cup/week, 1–3 
cups /month and almost never) into ≤1 cup/day (reference category)
Those who responded 6–10 cups/day in the total coffee 
questionnaire were categorized  as ≥ 8 cups/day (heavy consumers)
The final categories used in the analysis: 
≤1 cup/day (reference category), 2–3 cups/day, 4–7 cups/day and ≥8 cups/day (heavy consumers).
